リウマチ病セミナー　XXIII　2012

出版社： 永井書店
著者：
発行日： 2012-12-25
分野： 臨床医学：内科  >  膠原病/リウマチ
ISBN： 9784815919078
シリーズ： リウマチ病セミナー
電子書籍版： 2012-12-25 （初版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

9,020 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,510 円(税込)

購入する

商品紹介

リウマチ学のいまを知らせる好著。本セミナーは，1990年以来毎年発行されて，今回で23冊目。内容は，リウマチ病の捉え方に大きく影響する新しい知見とそれに基づく新しい考え方。リウマトロジーの醍醐味を教えてくれるリウマチ病研究の歴史。そして，今やリウマチ学の最大のテーマである骨粗鬆症の最新知見．多彩で新しい薬剤のレビュー，大きく進歩する手術技術などを取り上げる。常に本領域の水先案内人として，最新の研究成果・治療データを提供してきた。多彩で日進月歩の進展をみせるリウマチ学を一流の研究者たちが思う存分成果を披露している。

目次

  • リウマチ病セミナー　XXIII　2012

    ―目次―

    炎症リウマチ
    　Sjogren 症候群（Sjogren's syndrome）
    　全身性エリテマトーデス（SLE）の発症病因
    　　　?「自己臨界点説：Self-organized criticality theory of
    　　　　　 autoimmunity」?　
    　Palindromic Rheumatism再訪　　
    　多発性筋炎／皮膚筋炎 2011　
    　反応性関節炎 2011　
    　関節リウマチと睡眠障害　　

    骨関節，脊椎，神経
    　Fibrous Dysplasia 再訪　
    　胸鎖関節炎　
    　慢性の腰痛　
    　姿勢とリウマチ病のプライマリケア　
    　成人にみられるmild caudal regression syndrome　　
    　剣道によるスポーツ外傷・障害　

    燐・カルシウム代謝
    　高齢者骨粗鬆　

    検査，評価
    　足関節の内視鏡　

    生物学的反応
    　IL-7と関節リウマチ　　
    　免疫セマフォリン　　
    　Resolving Lipoxin　
    　腸性セロトニン　
    　iPS細胞を経ない皮膚細胞から軟骨細胞への誘導　

    治療と副作用
    運動器慢性疼痛とオピオイド　　
    　ワクチン接種によるリウマチ性疾患の治療　
    　関節リウマチ患者におけるハーブ足浴の効果　
    　骨髄腫の治療　　
    　OAに対する新しい分子標的治療薬　
    　関節リウマチに対する新しい分子標的治療薬　
    　ビタミンD3 の免疫調節作用　　
    　トファシチニブによるRA治療戦略　
    　抗IL-17抗体によるRAおよびSpAの治療　

    手　　　術
    　外反母趾の手術　
    　腰部脊柱管狭窄症に対する棘突起間スペーサー　
    　軟骨移植の進歩　　

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

P.9 掲載の参考文献
1) Sumida T et al. Autoimmunity Reviews 2010; 9:615.
PubMed
2) 藤林孝司ら. 厚生省特定疾患自己免疫疾患調査研究班, 平成10年度研究報告書, 1999:135-138.
 
3) Fujibayashi T et al. Mod Rheumatol 2004; 14:425.
PubMed
P.17 掲載の参考文献
1) Tsumiyama K, Miyazaki Y, Shiozawa S. Self-organized criticality theory of autoimmunity. PLos ONE 2009; 4:e8382.
PubMed
2) Shiozawa S. Pathogenesis of SLE and aiCD4 T cell:new insight on autoimmunity. Joint Bone Spine 2012; 79:428-430.
 
3) Nathan C, Ding A. Nonresolving inflammation. Cell 2010:140:871-182.
PubMed
4) Shiozawa S. The cause of systemic lupus erythematosus:implication of "self-organized criticality theory of autoimmunity" on the pathogenesis of systemic lupus erythematosus. Int J Rheum Dis 2010; 5:619-626.
 
5) Shiozawa S. The cause of SLE and the nature of immunity:contribution of unhealed inflammation to a novel"Self-organized criticality" theory of autoimmunity. Exp Rev Clin lmmunol 2012; 7:715-717.
 
P.25 掲載の参考文献
1) Guerne PA, Weisman MH. Palindromic rheumatism:part of or apart from the spectrum of rheumatoid arthritis. Am J Med 1992; 93:451-460.
PubMed
2) Hench PS, Rosenberg EF. Palindromic rheumatism. A new oft-recurring disease of joints (arthritis, periarthritis, paraarthritis)apparently producing no articular residues. Report of thirty-four cases. Arch Int Med 1944:73:293-321.
 
3) Sanmarti R, Canete JD, Salvador G. Palindromic rheumatism and other relapsing arthritis. Best Practice & Reserch Clinical Rheumatology 2004; 18:647-661.
 
4) 前田 晃. 回帰性リウマチは慢性関節リウマチの予備軍か? 七川歡次監修. リウマチ病セミナーII. 大阪:永井書店; 1991:80-87.
 
5) Pasero G, Barbieri P. Palindromic rheumatism: you just have to think about it. Clin Exp Rheumatol 1986; 4:197-199.
PubMed
6) Hannonen P, Motlonen T, Oka M. Palindromic rheumatism:a clinical survey of sixty patients. Scand J Rheumatol 1987; 16:413-420.
 
7) Bizzaro N, Mazzanti G, Tonutti E, et al. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001; 47:1089-1093.
PubMed
8) Salvador G, Gomez A, Vinas O, et al. Prevalence and clinical significance of anti-citrullinated peptide and antikeratin antibodies in palindromic rheumatism. An abortive form of rheumatoid arthritis? Rheumatology 2003; 42:972-975.
PubMed
9) Russel AS, Devani A, Maksymowych WP. The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palindromic rheumatism to rheumatoid arthritis. J Rheumatol 2006; 33:1240-1242.
 
10) Powell A, Davis P, Jones N, et al. Palindromic rheumatism is a common disease:comparison of new-onset palindromic rheumatism compared to new-onset rheumatoid arthritis in a 2-year cohort of patients. J Rheumatol 2008; 35:992-994.
 
11) Kaushik P. Palindromic rheumatism:a descriptive report of seven cases from North Dakota and a short review of literature. Clin Rheumatol 2010; 29:83-86.
 
12) Tamai M, Kawakami A, Iwamoto N, et al. Contribution of anti-CCP antibodies, proximal interphalangeal joint involvement, HLA-DRB 1 shared epitope, and PAD 14 as risk factors for the development of rheumatoid arthritis in palindromic rheumatism. Scand J Rheumatol 2010; 39:287-291.
 
13) Sanmarti R, Cabrera-Villalba Gomez-Puerta JA, et al. Palindromic rheumatism with positive anticitrullinated peptide/protein antibodies is not synonymous with rheumatoid arthritis. A longterm followup study. J Rheumatol 2012; 39:1929-1933.
PubMed
14) Koskinen E, Hannonen P, Sokka T. Palindromic rheumatism:longterm outcomes of 60 patients diagnosed in 1967-84. J Rheumatol 2009; 36:1873-1875.
PubMed
15) Tomiyama N, Higashiuesato Y, Oda T, et al. MEFV mutation analysis of familial Mediterranean fever in Japan. Clin Exp Rheumatol 2008:26:13-17.
PubMed
16) Canete JD, Arostegui JI, Queiro R, et al. Association of intermittent hydrarthrosis with MEFV gene mutations. Arthritis Rheum 2006; 54:2334-2335.
PubMed
17) Canete JD, Arostegui JI, Queiro R, et al. An unexpectedly high frequency of MEFV mutations in patients with anti-citrullinated protein antibody-negative palindromic rheumatism. Arthritis Rheum 2007; 56:2784-2788.
PubMed
P.35 掲載の参考文献
1) Bohan A, Peter JB. Polymyositis and dermatomyositis(first of two parts). N Engl J Med 1975; 292:344-347.
PubMed
2) 谷本潔昭. 皮膚筋炎・多発性筋炎の改訂診断基準. 厚生省特定疾患自己免疫疾患調査研究班 平成4年度研究報告書. 1993:25-28.
 
3) Christopher-Stine L. Neurologists are from Mars. Rheumatologists are from Venus:differences in approach to classifying the idiopathic inflammatory myopathies. Curr Opin Rheumatol 2010:22:623-626.
PubMed
4) Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis(dermatomyositis sine myositis)as a distinctive subset within the idiopathic inflammatory dermatomyo-pathies spectrum of clinical illness? J Am Acad Dermatol 2002; 46:626-636.
 
5) Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Reum 2005; 52:1571-1576.
 
6) 佐藤慎二. 抗CADM-140抗体の臨床的・病因的意義医学のあゆみ 2011; 239:77-82.
 
7) Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis:association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009; 60:2193-2200.
 
8) Yoshida K, Kurosaka D, Joh K, et al. Fasciitis as a common lesion of dermatomyositis, demonstrated early after disease onest by en bloc biopsy combined with magnetic resonance imaging. Arthritis Rheum 2010; 62:3751-3759
 
9) 吉田 健, 黒坂大太郎. 皮膚筋炎之炎症はどのように進展するか. リウマチ科 2011; 45:119-126.
 
10) Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis, N Engl J Med 1993:329:1993-2000.
PubMed
11) Hara M, Kinoshita M, Saito E, et al. Prospective study of high-dose intravenous immunoglobulin for the treatment of steroid-resistant polymyositis and dermatomyositis. Mod Rheumatol 2003:13:319-325.
PubMed
12) Saito E, Koike T, Hashimoto H et al. Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis. Mod Rheumatol 2008; 18:34-44.
PubMed
13) Miyasaka N, Hara M, Koike T, et al. Effects of intravenous immunoglobulin therapy in Japanese patients with polylnyositis and dermatomyositis resistant to corticosteroids:a randomized double-blind placebo-controlled trial. Mod Rheumatol 2012; 22:382-393.
PubMed
P.42 掲載の参考文献
1) 七川歡次. ライター症候群, 日本脊椎関節炎学会誌2011:Vol II(1):121-124.
 
2) Taurog JT. Reactive arthritis. Principles of Harrison's Internal Medicine. Fuaci AS, et al Eds, 17th Ed. New York:McGraw Hill Medical; 2010:2113-2115.
 
3) Towens JM. Reactive arthritis after enteric infections in the United States:The problem of definition. Clin Infect Dis 2010:50:247-254.
 
4) Uotila T, Antonen J, Laine J, et al. Reactive arthritis in a population exposed to an extensive water bone gastroenteritis outbreak after sewage contamination in Pirkanmaa Finland. Scand J Rheumatol 20011; 40:358-362.
 
5) Fan PT, Yu DTY. Reiter's syndrome. Textbook of Rheumatology 4th Ed Kelly W, Harris ED, et al. Eds. Philadelphia:WB Sauders Company:1993:961-973.
 
6) James C, Wei C, Huang F, et al. Identification of RGS 1 as a candidate biomarkers for undifferentiated spondyloarthritis by genome-wide expression profiling and real-time polymerase chain reaction. Arthritis Rheum 2009; 60:3269-3279.
 
7) Carter JD, Gerard HC, Espinoza LR, et al, Chlamydiae as etiologic agents in chronic undifferentiated spodyloarthritis. Arthritis Rheum 2009; 60:1311-1316.
 
8) Yin Z, Braun J, Neure L, et al. Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. Arthritis Rheum 1997; 40:1788-1797.
PubMed
9) Steiner G, Studnicke-Benke A, Witzmann G, et al. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis. J Rheumatol 1995; 22:406-412.
 
10) Shen H, Goodall JC, Gaston H. Frequency and phenotype of T helper 17 cells in peripheral bloo and synovial fluid of patients with reactive arthritis. J Rheumatol 2010; 37:2096-2099.
 
11) Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-mast cells contribute to synovial inflammation in spondyloarthritis. Arthritis Rheum 2012; 64:99-109.
PubMed
12) Glatigny S, Fert I, Blaton MA, et al. Proinflammatory Th 17 cells are expanded and induced by dendtric cells in spondyloarthritis-prone HLA-B 27-transgenic rats. Arthritis Rheum 2011:64:110-120.
 
13) Butrimiene I, Jarmalaite S, Venalis A, et al. Different cytokine profile in patients with chronic and acute reactive arthritis. Rheumatol 2004:43:1300-1304.
 
14) Singh R, Aggarwal A, Misra R. TH 1/Th 17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy. J Rheumatol 2007:34:2285-2290.
 
15) Kotake S, Scumacher HRJr, Yarboro CH, et al. In vitro gene expression of type 1 and type 2 cytokines in synovial tissues from patients in early stages of rheumatoid, reactive, and undifferentiated arthritis. Pross Assoc Am Physician 1997; 109:286-301.
 
16) Elicabe RJ, Cargnelutti E, Serer MI, et al. Lack of TNFR p 55 results in heightened expression of IFN-γand IL-17during the development of reactive arthritis. J Immunol 2010; 185:4485-4495.
 
17) Carter JD, Espinoza LR, Inman D, et al. Combination antibodies as a treatment for chronic Chlamydia-induced reactive arthritis. A double-blind, placebo-controlled, prospective trial. Arthritis Rheum 2011; 62:1208-1307.
 
18) Meyer A, Chtelus E, Wendling D, et al. Safety and efficacy of anti-TNF α therapy in 10 patients with recent-onset refractory reactive arthritis. Arthritis Rheum 2011:63:1274-1280.
 
19) Tanaka T, Kuwahara Y, Shima Y, et al. Successful treatment of reactive arthritis with anti-interleukin-6 receptor antibody, Tocilizumab. Arthritis Care&Rheum 2009; 61:1762-1764.
 
P.48 掲載の参考文献
1) Harkness JA, Richter MB, Panayi GS, et al. Circadian variation in disease activity in rheumatoid arthritis. Br Med J 1982:284:551-554.
 
2) Cutolo M, Masi AT. Circadian rhythms and arthritis. Rheum Dis Clin 2005; 31:115-129.
PubMed
3) Kawasaki H, Komai K, Ouyang Z, et al. c-Fos/activator protein-1 transactivates week kinase at G (1) /S to inhibit premature mitosis in antigen-specific Th 1 cells. EMBO J 2001; 20:4618-4627.
 
4) Okamura H, Miyake S, Sumi Y, et al. Photic induction of mPer 1 and mPer 2 in cry-deficient mice lacking a biologicalclock. Science 1999. 286:2531-2534.
 
5) Latman NS. Relation of menstrual cycle phase to symptoms of rheumatoid arthritis. Am J Med 1983; 74:957-960.
PubMed
6) Drewes AM, Svendsen L, Taagholt SJ, et al. Sleep in rheumatoid arthritis:a comparison with healthy subjects and studies of sleep/wake interactions. Br J Rheumatol 1998:37:71-81.
PubMed
7) Cakirbay H, Bilici M, Kavakci O, et al. Int Neurosci 2004; 114:245-256.
PubMed
8) Taylor-Gjevre RM, Gjevre JA, Nair B, et al. J Clin Rheumatol 2010; 16:255-261.
 
9) Goodchild CE, Treharne GJ, Booth DA, et al. Musculoskeletal Care 2010; 8:107-117.
PubMed
10) Zamarrion C, Maceiras F, Mera A, et al. Ann Rheum Dis 2004; 63:88-90.
 
11) Parker JC, Smarr KL, Angelone EO, et al. Arthritis Care Res 1992; 5:196-201.
PubMed
12) Kojima M, Kojima T, Suzuki S, et al. Arthritis Rheum 2009; 61:1018-1024.
PubMed
P.55 掲載の参考文献
1) Lichtenstein L, Jaffe HL. Fibrous dysplasia of bone. Arch Pathol 1942:33:777-816.
 
2) DiCaprio MR, Enneking WF. Fibrous dysplasia. Pathophysiology, evaluation, and treatment. J Bone Joint Surg Am 2005; 87:1848-1864.
PubMed
3) Unni KK, Inwards CY, Bridge JA, et al. Fibrous dysplasia. In:Silverberg SG editor. Tumors of the bones and joints, ARP Press, Maryland, 2005:337-343.
 
4) Hart ES, Kelly MH, Brillante B, et al. Onset, progression, and plateau of skeletal lesions in fibrous dysplasia and the relationship to functional outcome. J Bone Miner Res 2007; 22:1468-1474.
PubMed
5) Wirth WA, Leavitt D, Enzinger FM. Multiple intramuscular myxomas. Another extraskeletal manifestation of fibrous dysplasia. Cancer 1971; 27:1167-1173.
PubMed
6) Dent CE, Gertner JM. Hypophosphataemic osteomalacia in fibrous dysplasia. Q J Med 1976; 45:411-420.
PubMed
7) Dumitrescu CE, Collins MT. McCune-Albright syndrome. Orphanet J Rare Dis 2008; 3:1-12.
PubMed
8) Ruggieri P, Sim FH, Bond JR, et al. Malignancies in fibrous dysplasia. Cancer 1994; 73:1411-1424.
PubMed
9) Lopez-Ben R, Pitt MJ, Jaffe KA, et al. Osteosarcoma in a patient with McCune-Albright syndrome and Mazabraud's syndrome. Skeletal Radiol 1999; 28:522-526.
 
10) Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991; 325:1688-1695.
PubMed
11) Bianco P, Riminucci M, Majolagbe A, et al. Mutations of the GNAS 1 gene, stromal cell dysfunction, and osteomalacic changes in non-McCune-Albright fibrous dysplasia of bone. J Bone Miner Res 2000:15:120-128.
 
12) 豊澤 悟. 線維性骨異形成症の分子生物学. 生体の科学2007; 58:219-223.
 
13) Weinstein LS, Chen M, Liu J. Gs(alpha)mutations and imprinting defects in human disease. Ann N Y Acad Sci 2002; 968:173-197.
PubMed
14) Okamoto S, Hisaoka M, Ushijima M, et al. Activating Gs(alpha)mutation in intramuscular myxomas with and without fibrous dysplasia of bone. Virchows Arch 2000; 437:133-137.
PubMed
15) Candeliere GA, Roughley PJ, Glorieux FH. Polymerase chain reaction-based technique for the selective enrichment and analysis of mosaic arg 201 mutations in G alpha s from patients with fibrous dysplasia of bone. Bone 1997:21:201-206.
 
16) Riminucci M, Fisher LW, Majolagbe A, et al. A novel GNAS1 mutation, R201G, in McCune-Albright syndrome. J Bone Miner Res 1999:14:1987-1989.
PubMed
17) Marie PJ, de Pollak C, Chanson P, et al. Increased proliferation of osteoblastic cells expressing the activating Gs alpha mutation in monostotic and polyostotic fibrous dysplasia. Am J Pathol 1997; 150:1059-1069.
PubMed
18) Shenker A, Weinstein LS, Moran A, et al. Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. J Pediatr 1993; 123:509-518.
PubMed
19) Kim I, Kim ER, Nam HJ, et al. Activating mutation of GS alpha in McCune-Albright syndrome causes skin pigmentation by tyrosinase gene activation on affected melanocytes. Horm Res 1999; 52:235-240.
PubMed
20) Spiegel AM, Shenker A, Weinstein LS. Receptor-effector coupling by G proteins:implications for normal and abnormal signal transduction. Endocr Rev 1992; 13:536-565.
PubMed
21) Candeliere GA, Glorieux FH, Prud'homme J, et al. lncreased expression of the c-fos proto-oncogene in bone from patients with fibrous dysplasia. N Engl J Med 1995:332:1546-1551.
 
22) Stein GS, Lian JB. Molecular mechanisms mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype. Endocr Rev 1993; 14:424-442.
PubMed
23) Yamamoto T, Ozono K, Kasayama S, et al. Increased IL-6-production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. J Clin Invest 1996; 98:30-35.
PubMed
24) Motomura T, Kasayama S, Takagi M, et al. Increased interleukin-6 production in mouse osteoblastic MC 3T 3-E 1 cells expressing activating mutant of the stimulatory G protein. J Bone Miner Res 1998; 13:1084-1091.
 
25) Collins MT, Chebli C, Jones J, et al. Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia. J Bone Miner Res 2001; 16:806-813.
PubMed
26) Riminucci M, Collins MT, Fedarko NS, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003:112:683-692.
PubMed
27) Sacchetti B, Funari A, Michienzi S, et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007; 131:324-336.
PubMed
28) Bianco P, Kuznetsov SA, Riminucci M, et al. Reproduction of human fibrous dysplasia of bone in immunocompromised mice by transplanted mosaics of normal and Gsalpha-mutated skeletal progenitor cells. J Clin Invest 1998; 101:1737-1744.
PubMed
29) Piersanti S, Remoli C, Saggio I, et al. Transfer, analysis, and reversion of the fibrous dysplasia cellular phenotype in human skeletal progenitors. J Bone Miner Res 2010; 25:1103-1116.
PubMed
30) Riminucci M, Fisher LW, Shenker A, et al. Fibrous dysplasia of bone in the McCune-Albright syndrome:abnormalities in bone formation. Am J Pathol 1997:151:1587-1600.
PubMed
31) Toyosawa S, Yuki M, Kishino M, et al. Ossifying fibroma vs fibrous dysplasia of the jaw:molecular and immunological characterization. Mod Pathol 2007; 20:389-396.
PubMed
32) Bertoni F, Bacchini P, Fabbri N, et al. Osteosarcoma. Low-grade intraosseous-type osteosarcoma histologically resembling parosteal osteosarcoma, fibrous dysplasia, and desmoplastic fibroma. Cancer 1993; 71:338-345.
PubMed
33) Voytek TM, Ro JY, Edeiken J, et al. Fibrous dysplasia and cemento-ossifying fibroma A histologic spectrum. Am J Surg Pathol 1995; 19:775-781.
 
34) Pollandt K, Engels C, Kaiser E, et al. Gsalpha gene mutations in monostotic fibrous dysplasia of bone and fibrous dysplasia-like low-grade central osteosarcoma. Virchows Arch 2001:439:170-175.
PubMed
35) Sakamoto A, Oda Y, Iwamoto Y, et al. A comparative study of fibrous dysplasia and osteofibrous dysplasia with regard to Gsalpha mutation at the Arg 201 codon:polymerase chain reaction-restriction fragment length polymorphism analysis of paraffin-ernbedded tissues. J Mol Diagn 2000; 2:67-72.
 
36) Patel MM, Wilkey JF, Abdelsayed R, et al. Analysis of GNAS mutations in cemento-ossifying fibromas and cemento-osseous dysplasias of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109:739-743.
PubMed
37) Liens D, Delmas PD, Meunier PJ, et al. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet 1994; 343:953-954.
PubMed
38) Chapurlat RD, Hugueny P, Delmas PD, et al. Treatment of fibrous dysplasia of bone with intravenous pamidronate:long-term effectiveness and evaluation of predictors of response to treatment. Bone 2004; 35:235-242.
PubMed
39) Chapurlat RD. Medical therapy in adults with fibrous dysplasia of bone. J Bone Miner Res 2006; 21:114-119.
 
P.62 掲載の参考文献
1) 吉村英哉. 胸鎖関節に関する解剖学的研究～鎖骨間靱帯の形態について～. 肩関節2009:33:595-597.
 
2) 福田宏明, 伊勢亀富士朗, 戸松泰介ら. 胸鎖関節機能とその障害の吟味. 整形外科1973; 24:971-983.
 
3) Inman VT, Saunders JB, Abbott LC:Observations on the functionof the shoulder joint. J Bone Joint Surg 1944; 26:1-30.
 
4) 川崎 拓. 胸鎖関節の病態. リウマチ病セミナーXII. 七川歡次監修. 大阪:永井書店; 2001:137-146.
 
5) 村田洋一, 首藤敏秀, 山岡和弘ら. 著明な胸鎖関節破壊を来したSAPHO症候群と考えられた1例. 整形外科と災害外科2009; 58:451-455.
 
6) 杜若陽祐, 宮田裕子, 伊藤泰教ら. SAPHO症候群の1例:脊椎病変の画像所見を中心に. 宮崎医学会誌 2009; 33:132-137.
 
7) Dahrlert W:SAPHO syndrome. Radiology review manual. Lippincott Williams & wilkins, 2007; 160.
 
8) 向井知之, 高橋美裕希, 服部大哉ら. 中年期に診断された胸肋鎖関節病変を伴う強直性脊椎炎の2例. 日本脊椎関節炎学会2009; Vol. 1(No. 2):69-73.
 
9) Sonozaki H, Furusawa S, Seki H, et al. Four cases with symmetrical ossifications between the clavicles and the first ribs on both sides. Kanto J Orthop Trauma 1974; 5:244-247.
 
10) 川崎 拓, 松本圭司, 福田眞輔ら. 結核性胸鎖関節炎の一例. 日関誌1993; 12:311-316.
 
11) 中島恭哉, 清水義友, 田辺勝久. 若年成人に発症した化膿性胸鎖関節炎の1例. 中部整災誌2009; 52:1385-1386.
 
12) Ross JJ, et al. Sternoclavicular septic arthritis:Review of 180 cases. Medicine(Baltimore)2004; 83:139-148.
PubMed
13) Dubost JJ, et al. No changes in the distribution of organisms responsible for septic arthritis over a 20 year period Ann Rheum Dis 2002; 61:267-269.
 
P.69 掲載の参考文献
1) 矢吹省司, 牛田享宏, 竹下克志ら. 日本における慢性疼痛保有者の実態調査Pain in Japan 2010より. 臨整外2012; 47:127-134.
 
2) Boos N, Weissbach S, Rohrbach H, et al. Classification of age-related changes in lumbar intervertebral discs. Spine 2002; 27:2631-2644.
PubMed
3) Boden SD, Davis DO, Dina TS, et al. Abnormal magnetic-resonance scans of the lumbar spine in asymptpmatic subjects. A prospective investigation. J Bone Joint Surg[Am] 1990; 72:403-408.
 
4) Boos N, Rieder R, Schade V, et al. The diagnostic accuracy of magnetic resonance imaging, work perception, and psychosocial factors in identifying symptomatic disc herniation. Spine 1995:20:2613-2625.
PubMed
5) Savage RA, Whitehouse GH, Roberts N, et al. The relationship between the magnetic resonance imaging appearance of the lumbar spine and low back pain, age and occupation in males. Eur Spine J 1997; 6:106-114.
PubMed
6) Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA 1992; 268:760-765.
PubMed
7) Bogduk N, What's in a name? The labeling of back pain. Med J Aust 2000; 173:400-401.
 
8) Carragee EJ, Chen Y, Tanner CM, et al. Can discography cause long-term back symptoms in previously asymptomatic subjects?. Spine 2000; 25:1803-1808.
PubMed
9) Birrell F, Croft P, Cooper C, et al. Health impact of pain in the hip region with and without radiographic evidence of osteoarthritis:a study of new attenders to primary care. The PCR Hip Study Group. Ann Rheum Dis 2000; 59:857-863.
 
10) Kikuchi S. International collaboration beyond the culture gap. Spine 2007; 32:1369-1374.
PubMed
11) Kikuchi S. New concept for backache:biopsychosocial pain syndrome. Eur Spine J 2008:17(Suppl 4):S 421-S 427.
 
12) Airaksinen O, Brox JI, Cedraschi C, et al. Chapter 4. European guidelines for the management of chronic nonspecific low back pain. Eur Spine J 2006:Supple 2:S 192-S 300. (www. backpaineurope. org)
 
13) Chou R, Qaseem A, Snow V, et al. Diagnosis and Treatment of Low Back Pain:A Joint Clinical Practice Guideline from the American College of Physicians and the American Pain Society. Ann Intern Med 2007:147:478-491. (www. annals. org/content/147/7/478. full)
 
14) Bendix AE, Bendix T, Haestrup C, et al. A prospective, randomized 5-year follow-up study of functional restoration in chronic low back pain patients. Eur Spine J l 998; 7:111-119.
 
15) Philadelphia panel members. Philadelphia panel evidence-based clinical practice guidelines on selected rehabilitation interventions for low back pain. Physical Therapy 2001:81:1641-1674,
 
16) Standaert CJ, Weinstein SM, Rumpeltes J. Evidence-informed management of chronic low back pain with lumbar stabilization exercise. Spine J 2008; 8:114-120.
PubMed
17) Mayer J, Mooney V, Dagenais S. Evidence-informed management of chronic low back pain with lumbar extensor strengthening exercises. Spine J 2008; 8:96-113.
PubMed
18) Levine JD, Gordon NC. Influence of the method of drug administration on analgesic response. Nature 1984; 312:755-756.
PubMed
19) Finniss DG, Kaptchuk TJ, Miller F, et al. Biological, clinical, and ethical advances of placebo effects. Lancet 2010; 375 (9715):686-695.
PubMed
20) 矢吹省司. “プラセボ効果”について思う. ペインクリニック2010; 31:989-990.
 
21) Turner JA Deyo RA, Loeser JD, et al. The importance of placebo effects in pain treatment and research. JAMA 1994:271:1609-1614.
PubMed
22) 矢吹省司, 二階堂琢也, 紺野愼一. 慢性腰痛に対するリエゾンアプローチ. からだの科学2010; 266:115-118.
 
23) 松下 隆, 矢吹省司, 牛田享宏ら. 変形性膝関節症または腰痛症に伴う慢性疼痛を有する患者に対するトラマドール塩酸塩/アセトアミノフェン配合錠の第III相臨床試験? プラセボを対照としたランダム化治療中止二重盲検群間比較試験?. 臨床整形外科2011; 46:825-835.
 
24)矢吹省司. ブプレノルフィン(貼付剤). Modern Physician 2012; 32:43-45.
 
P.75 掲載の参考文献
1) 中村隆一, 臨床運動学第3版. 東京:医歯薬出版; 2002:403-471
 
2) Barlow W. Postural homoeostasis. Rheumatology 1952:1:77-87.
 
3) 渡會公治. 美しく立つ. 文光堂; 2007.
 
4) 志水正敏. ストレスと慢性関節リウマチ. 七川歡次監修. リウマチ病セミナー IX. 大阪:永井書店:1998:31-37.
 
5) 志水正敏. リウマチ病患者に多い訴えとその対策.七川歡次監修. リウマチ病セミナーXIX.大阪:永井書店; 2008:151-158.
 
6) Stenstrom CH, Minor MA. Evidence for the benefit of aerobic and strengthening exercise in rheumatoid arthritis. Arthritis Rheum 2003:15; 49:428-434.
 
7) Eurenius E, Stenstrom CH Physical activity, physical fitness, and general health perception among individuals with rheumatoid arthritis. Arthritis Rheum 2005; 15; 53:48-55.
 
8) Work Group Recommendations:2002 Exercise and Physical Activity Conference, St Louis, Missouri-Session VI:Population Approaches to Health Promotion and Disability Prevention Through Physical Activity Arthritis Rheum 2003; 49:477,
 
9) Stenstrom CH. Therapeutic exercise in rheumatoid arthritis, Arthritis Care Res 1994; 7:190-197.
PubMed
10) Barlow W. The Alexander Principle. AM Heath and Company Ltd London.
 
11) Wバーロウ. アレクサンダー・テクニーク. 伊東 博訳. 誠信書房:1989.
 
12) Tinbergen N Ethology and stress diseases 1973 Nobel Lecture 1973.
 
13) Mehling WE, Wrubel J, Daubenmier JJ, et al. Body Awareness:a phenomenological inquiry into the common ground of mind-body therapies. Philos Ethics Humanit Med 2011; 6:6.
PubMed
14) Wang C, Schmid CH, Rones R, et al. A randomized trial of tai chi for fibromyalgia. N Engl J Med 2010; 363:743-754.
PubMed
15) Wang C. Tai chi and rheumatic diseases. Rheum Dis Clin North Am 2011; 37:19-32.
 
P.87 掲載の参考文献
1) 西林保朗, 吉本沙織. 坐骨神経痛の炎症因子. 七川歡次監修. リウマチ病セミナーXVIII. 大阪:永井書店; 2007:90-101.
 
2) 井口哲弘, 金村在哲, 赤浦潤也ら. 腰椎不安定症. 七川歡次監修. リウマチ病セミナーXIII. 大阪:永井書店; 2002:71-80.
 
3) 西林保朗. 靱帯のhyperlaxityと過度運動性症候群. 七川歡次監修. リウマチ病セミナーX. 大阪:永井書店; 1999:115-132.
 
4) Kirkaldy-Willis WH.5 Pathology and pathogenesis of low back pain. Kirkaldy-Willis WH, Bernard TN, Jred. Managing low back pain, 4thed. New York:Churchill Livingstone; 1999:65-96.
 
5) 西林保朗. 若年者の椎間板. 七川歡次監修. リウマチ病セミナーVI. 大阪:永井書店; 1995:102-118,
 
6) 古川哲雄. 35. 成人にみられる mild caudal regression syndrome. ヤヌスの顔-神経内科臨床ノート-. 東京:科学評論社; 1989:138-139.
 
7) Koehler A, Zimmer EA. 5. Vertebral Column, Lumbar Spine. Borderlands of the normal and early pathologic in skeletal roentgenology 3rd American edition New York:Thieme; 1993:530-566.
 
8) 古川哲雄. 2. 正常人にみられるneglect syndrome. 続ヤヌスの顔-背面思考の神経内科学-. 東京:科学論評社:1992:4-11.
 
9) 西林保朗. 脊椎後彎の臨床再訪-頸椎後彎(首垂れ症):“隠れ首垂れ症”を探そう-. 七川歡次監修. リウマチ病セミナーXXII. 大阪:永井書店:2011:97-112,
 
10) American college of rheumatology ad hoc committee on clinical guidelines. Guidelines for the initial evaluation of the adult patient with acute musculoskeletal symptoms. GALS locomotor screening system. Arthritis Rheum 1996; 39:1-8.
 
11) http://www.joa.or.jp/jp/public/10como/mads.html(公益社団法人日本整形外科学会ホームページ)新概念「ロコモティブシンドローム(運動器症候群)」とは. 「運動器不安定症」とは
 
12) 西林保朗, 小形晶子. 筋筋膜痛症候群. 七川歡次監修. リウマチ病セミナーXVII. 大阪:永井書店; 2006:101-113.
 
13) Allan DB, Waddell G. An historical perspective on low back pain and disability. Acta Orthop Scand 1989; 60 (Suppl 234):1-23.
 
14) 有田親史. 慢性腰痛患者に対するfunctional restoration. 七川歡次監修 リウマチ病セミナーXV. 大阪:永井書店; 2004:60-68.
 
15) Kirkaldy-Willis WH, Bernard Jr TN. 1 A new look at an old problem. Kirka-Willis WH, Bernard, Jr TN ed. Managing low back pain, 4th ed. NewYork:Churchill Livingstone: 1999:3-9.
 
16) 古川哲雄. 2.正常人にみられる保続. 続々ヤヌスの顔-人間学として神経内科学-. 東京:科学論評社:1995:4-10.
 
P.98 掲載の参考文献
1) 高幣民雄. 剣道, 林光俊 編:ナショナルチームドクターが書いた種目別スポーツ障害の診療 1版. 東京:南江堂; 2007:360-369.
 
2) スポーツ安全協会編:スポーツ安全保険の加入者および各種事故の統計データ 平成22年度版. 東京:(財) スポーツ安全協会:2012:16-20.
 
3) 全日本剣道連盟医科学委員会編:剣道医学救急ハンドブック 1版. 東京:(財)全日本剣道連盟; 2003:5.
 
4) 高橋伸太郎, 高幣民雄, 佐々木健ら. 剣道国体選手に生じたアキレス腱断裂の1例, 千葉スポーツ医学研究会雑誌2011; 8:1-4
 
5) 全日本剣道連盟医科学委員会編:剣道医学Q&A 1版. 東京:(財)全日本剣道連盟; 2001:146-147.
 
6) 高幣民雄, 佐々木健, 百鬼史訓ら. アキレス腱断裂予防のために. 月刊剣窓2003; 260:20-25.
 
7) 佐藤和敬, 柚木 脩. 剣道選手のアキレス腱断裂について. 関西臨床スポーツ医・科学研究会誌2000; 10:51-53.
 
8) 津山直一, 中村耕三 監修. 整形外科クルズス 改訂4版. 東京:南江堂; 2003:756.
 
9) 貴志真也, 左海伸夫, 廣橋賢次ら. 剣道選手の下腿・足部痛に関する一考察. 日本臨床スポーツ医学会誌 2002; 10:82-89.
Medical*Online
10) 黒澤 尚, 星川吉光, 高尾良英ら編. ・下肢. スポーツ外傷学 1版. 東京:医歯薬出版; 2001:268-271.
 
11) 久野木順一. 痛みのタイプ別・腰痛の最新治療法. 専門医がやさしく教える腰痛 東京:PHP研究所; 1999:62-77.
 

燐・カルシウム代謝

P.109 掲載の参考文献
1) Yosimura N, Kinosita H, Oka H et al Cumrative incidence and changes in prevarence of vertebral fracture in a rural japanese community:A 10-years follow-up of the Miyama cohort. Archives Osteoporosis DOI 2006;10.1007/s1165.006-oo6-o.
 
2) 吉村典子. 骨粗鬆症の罹患率の現況と今後の動向. 骨粗鬆症治療2008; 7:10-15.
 
3) 吉村典子, 岡 敬之, 村木重之ら. 骨粗鬆症の有病率の推移と発生率の推定. osteoporosis Jpn 2006; 14 suppl:140-149.
 
4) 折茂 肇(骨粗鬆症の予防と治療ガイドライン作成委員会). 骨粗鬆症の治療-薬物治療開始基準.骨粗鬆症の予防と治療ガイドライン2006版. 東京:三法社; 2006:50-53.
 
5) Kanis JA, Bergstrom, Laet C, et al. Assessment of fracture risk. Osteoporosis Int 2005; 16:561.
 
6) 奥村法昭, 今井晋二. 骨折リスクの評価. リウマチ病セミナーXXI. 七川歡次監修. 大阪:永井書店; 2010:137-144.
 
7) 細井孝之. 骨折リスク評価ツール(FRAX). 骨粗鬆症治療2010; 9:73-77.
 
8) 宗閻 聡. 年齢別・重症度別骨吸収剤の使い分け. Bone Joint Nerve 2010; 2:297-312.
 
9) 折茂 肇. 骨粗鬆症の薬物治療. 骨粗鬆症の予防と治療ガイドライン2006版. 東京:三法社; 2006:73-102.
 
10) 折茂 肇. 続発性骨粗鬆症. 骨粗鬆症の予防と治療のガイドライン2006版. 東京:三法社; 2006:103-108.
 
11) Kouda K, lki M, Fujita Y, et al. Alcohol intake and bone status in elderly Japanese men:Baseline data from the Fujiwara-kyo osteoporosis risk in Mem(Formen)study. Bone 2011; 49:275-280.
 
12) Karantana A, Boulton C, Bouliotis G, et al. Epidemiology and outcome of fracture of the hip in womem aged 65 years and under. J Bone Joint Surg 2011; 93-(Br)93-B:658-664.
 
13) 白木正孝. 骨粗鬆症の治療ガイドライイン. 骨粗鬆症のマネイジメント. 東京:三法社; 2010:110-113.
 
14) Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003; 61:1104-1107.
PubMed
15) Advisory Task Force on Bisphonate related Osteonecrosis of the jaws. American Association of Oral and Maxillo-facial Surgeon position paper on bisphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65:369-376.
 
16) 島原政司. 顎骨壊死. 骨粗鬆症治療2008:7:69-71.
 
17) 米田俊之. ビスホスホネート関連顎骨壊死の病態とそのマネジメント. 骨粗鬆症のマネジメント. 大阪:医薬ジャーナル社:2010:202-208.
 
18) Odivina CV, Levy S, Rao S, et al. Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clon Endocrinol(Oxford)2010; 72:161-168.
 
19) Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on andronate therapy. J Bone Joint Surg Br 2007; 89:349-353.
 
20) Lenart RA, Lorish DG, Lane JM. A typical fractures of the femoral diaphysis in postmenopausal women taking andronate. N Engl J Med 2008; 358:1304-1306.
 
21) Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011; 364:1728-1737.
PubMed
22) Kyrgidis A, Toulis KA. Denusiomab-related osteonecrosis of the jaws. Osteoporos Int 2011; 22:369-370.
PubMed
23) Tsourdi E, Rachner TD, Gruber M et al. Seizures associated with zoledronic acid for osteoporosis. J Clin Endocrinol Metab 2011; 96:1955-1959.
 
24) Sharma B, DeCross AJ. Zenker's diverticulitis secondary to alendronate ingestion:a rare cause of recurrent disphagia Gastroentest Endoscop 2011; 73:368-370.
 
25) 千田益生, 堅山佳美, 雑賀建多. 転倒・転落の予防と対策-運動療法. 骨粗鬆症治療2010:7:37-49.
 
26) 奥泉宏康. ビタミンDなどの薬物療法を中心とした転倒予防. 骨粗鬆症治療2010:7:44-50.
 
27) 水沼英樹, 吉村典子, 曽根照喜ら. 骨粗鬆症検診-現状と課題:骨粗鬆症治療2008; 10:9-55.
 
28) 楊 鴻生. QUSによる骨粗鬆症検診の現状と課題. Bone Joint Nerve. 2011; 1:267-272.
Medical*Online
29) Parikh S, Brookhart M, Stedman M, et al. Correlation of nursing home characteristics with prescription of osteoporotisis medications. Bone 2011; 48:1164-1165.
PubMed
30) Beaupre LA, Manjumdar SR, Dieleman S, et al. Diagnosis and treatment of osteoporosis before And admission to longterm care institution. Osteoporos Int 2011; 10:1582-1585.
 
31) Simone MJ, Roberts DH, Irish J, et al. An educational intervation for providers to promote bone health in high risk older patient. J Am Geriatr Soc 2011; 59:291-296.
 
P.110 掲載の参考文献
1) 折茂肇.骨粗鬆症の予防と治療ガイドライン2006年版.東京:ライフサイエンス出版KK;2006.
 
2) 松本俊夫.骨粗鬆症のマネジメント.大阪:医薬ジャーナル社;2010.
 
3) 中村利孝監訳.Bartl R,Frisch B,Osteoporosis:A practical guide for all physicians-from pediatrics to geriatrics.東京:メヂィカル・サイエンス・インターナショナルKK:2007.
 
4) 小澤利男.老年医学と老年学.東京:ライフサイエンス出版KK;2009.
 
5) 伊藤雅治ら.国民衛生の動向・厚生の指標.厚生統計協会.東京,:2007.
 
6) 伊藤雅治ら.国民衛生の動向・厚生の指標.厚生統計協会.東京:2010.
 
14) Odivina
 

検査,評価

P.115 掲載の参考文献
1) Burman MS. Arthroscopy or the direct visualization of joints. An experimental cadaver study. J Bone Joint Surg 1931; 13:669-695.
PubMed
2) 高木憲次. 関節鏡. 日整会雑誌1939; 14:359-384.
 
3) 渡辺正毅. 関節鏡の現況と将来. 外科治療1972; 26:73-77.
 
4) 陳永振. 生体および屍体の足関節鏡視の研究. 日整会雑誌1976:50:631-651.
 
5) Plank E. Arthroscopy of the ankle joint. Hefte Unfallheilkd 1978:131:245-251.
PubMed
6) Takao M, Ochi M, Shu N, et al. Bandage distraction technique for ankle arthroscopy. Foot Ankle Int 1999; 20:389-391.
PubMed
7) Takao M, Ochi M, Naito K, et al. Arthroscopic drilling for chondral, sunchondral, and combined chondral-subchondral lesions of the talar dome. Arthroscopy 2003; 19:524-530.
 
8) Takao M, Uchio Y, Kakimaru H, et al. Arthroscopic drilling with debridement of remaining cartilage for ostechondral lesions of the talar dome in unstable ankles. Am J Sports Med 2004; 32:332-336.
 
9) Niki H, et al. Development and reliability of a standard rating system for outcome measurement of foot and ankle disorders I:development of standard rating system. J Orthop sci 2005; 10:457-465.
PubMed
10) Niki H, et al. Development and reliability of a standard rating system for outcome measurement of foot and ankle disorders I:interclinician and intraclinician reliability and validity of the newly established standard rating scales and Japanese Orthopaedic Association rating scale. J Orthop sci 2005; 10:466-474.
PubMed
11) Kolker D, Murray M, Wilson M. Osteochondral defects of the talus treated with autologous bone grafting. J Bone Joint Surg Br 2004; 86:521-526.
PubMed
12) Takao M, lnnami K, Komatsu F, et al. Retrograde cancellous bone plug transplantation for the treatment of advanced osteochondral lesions with large subchondral lesions of the ankle. Am J Sports Med 2010:38:1653-1660.
 

生物学的反応

P.122 掲載の参考文献
1) 佐伯行彦. 生物学的製剤 Up-date. 七川歓次監修. リウマチ病セミナーXXI. 大阪:永井書店; 2010:184-189.
 
2) Garber K. Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis, Nat Biotechnol 2011; 29:467-468.
 
3) Churchman SM, Ponchel F. Interleukin-7 in rheumatoid arthritis. Rheumatology(Oxford)2008; 47:753-759.
PubMed
4) Hewitt SL, Chaumeil J, Skok JA. Chromosome dynamics and the regulation of V(D)J recombination. Immunol Rev 2010; 237:43-54.
PubMed
5) Tan JT, Dudl E, LeRoy E, et al. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc Natl Acad Sci U S A 2001; 98:8732-8737.
PubMed
6) Sawa Y, Arima Y, Ogura H, et al. Hepatic interleukin-7 expression regulates T cell responses. Immunity 2009; 30:447-457.
PubMed
7) Yao Z, Cui Y, Watford WT, et al. Stat 5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci U S A 2006; 103:1000-1005.
 
8) Hoelbl A, Kovacic B, Kerenyi MA, et al. Clarifying the role of Stat 5 in lymphoid development and Abelson-induced transformation. Blood 2006; 107:4898-4906.
 
9) Jiang Q, Li WQ, Aiello FB, et al. Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev 2005; 16:513-533.
 
10) Wofford JA, Wieman HL, Jacobs SR, et al. IL-7 promotes Glut 1 trafficking and glucose uptake via STAT 5-mediated activation of Akt to support T-cell survival. Blood 2008; 111:2101-2111.
 
11) Toraldo G, Roggia C, Qian WP, et al. IL 7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factorαfrom T cells. Proc Natl Acad Sci U S A 2003; 100:125-130.
 
12) Weitzmann MN, Cenci S, Rifas L, et al. Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell prc)duction of soluble osteoclastogenic cytokines. Blood 2000; 96:1873-1878.
 
13) Weitzmann MN, Roggia C, Toraldo G, et al. Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J Clin Invest 2002; 110:1643-1650.
PubMed
14) Watanabe M, Ueno Y, Yajima T, et al. Interleukin 7 transgenic mice develop chronic colitis with decreased interleukin 7 protein accumulation in the colonic mucosa. J Exp Med 1998; 187:389-402.
PubMed
15) Uehira M, Matsuda H, Hikita I, et al. The development of dermatitis infiltrated by γ o T cells in IL-7 transgenic mice. Int Immunol 1993; 5:1619-1627.
 
16) Harada S, Yamamura M, Okamoto H, et al. Production of interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum 1999:42:1508-1516.
PubMed
17) van Roon JA, Verweij MC, Wijk MW, et al. Increased intraarticular interleukin-7 in rheumatoid arthritis patients stimulates cell contact-dependent activation of CD 4(+)Tcells and macrophages. Arthritis Rheum 2005; 52:1700-1710.
 
18) van Roon JA, Hartgring SA, Wenting-van Wijk M, et al. Persistence of interleukin 7 activity arld levels on tumour necrosis factorαblockade in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66:664-669.
 
19) Hartgring SA, van Roon JA, Wenting-van Wijk M, et al. Elevated expression of interleukin-7 receptor in inflamed joints mediates interleukin-7-induced immune activation in rheumatoid arthritis. Arthritis Rheum 2009; 60:2595-2605.
PubMed
20) Timmer TC, Baltus B, Vondenhoff M, et al. Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology:identification of the interleukin-7 signaling pathway in tissues with lymphoid neogenesis. Arthritis Rheum 2007; 56:2492-2502.
PubMed
21) van Roon JA, Glaudemans KA, Bijlsma JW, et al. Interleukin 7 stimulates tumour necrosis factorα and Th 1 cytokine production in joints of patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62:113-119.
 
22) Sawa S, Kamimura D, Jin GH, et al. Autoimmune arthritis associated with mutated IL-6 receptor gp 130 is driven by STAT 3/IL-7-dependent homeostatic proliferation of CD 4+Tcells. J Exp Med 2006; 203:1459-1470.
 
23) Kamimura D, Ishihara K, Hirano T. IL-6 signal transduction and its physiological roles:the signal orchestration model. Reviews of Physiology, Biochemistry and Pharmacology, 2004; 149:1-38.
 
24) Ohtani T, Ishihara K, Atsumi T, et al. Dissection of signaling cascades through gp 130 in vivo:Reciprocal roles for STAT 3-and SHP 2-mediated signals in immune responses. Immunity 2000; 12:95-105.
 
25) Atsumi T, Ishihara K, Kamimura D, et al. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp 130 causes autoimrnune arthritis. Journal of Experimental Medicine 2002:196:979-990.
 
26) Koetz K, Bryl E, Spickschen K, et al. T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci USA 2000; 97:9203-9208.
PubMed
27) Ponchel F, Morgan AW, Bingham SJ, et al. Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. Blood 2002; 100:4550-4556.
PubMed
28) Ponchel F, Verburg RJ, Bingham SJ, et al. Interleukin-7 deficiency in rheumatoid arthritis:consequences for therapy-induced lymphopenia. Arthritis Res Ther 2005:7:R 80-92.
 
29) Calzascia T, Pellegrini M, Lin A, et al. CD 4 T cells, lymphopenia and IL-7 in a multistep pathway to autoimmunity. Proc Natl Acad Sci U S A 2008; 105:2999-3004.
 
30) Gonzalez-Quintial R, Lawson BR, Scatizzi JC, et al. Systemic autoimmunity and lymphoproliferation are associated with excess IL-7 and inhibited by IL-7R α blockade. PLos One 2011; 6:e 27528.
 
P.130 掲載の参考文献
1) Luo Y, Raible D, Raper JA. Collapsin:a protein in brain that induces the collapse and paralysis of neuronal rowth cones. Cell 1993; 75:217-227.
 
2) Kolodkin AL, Matthes DJ, Goodman CS. The semaphoring genes encode a family of transmembrane and secreted rowth cone guidance molecules. Cell 1993; 75:1389-1399.
 
3) Semaphorine Nomenclature Committee. Unified nomenclature for the semaphorins/collapsins. Cell 1999; 97:551-552.
 
4) Suzuki K, Kumanogoh A, Kikutani H. Semaphorins and their receptors in immune cell interactions. Nature immunology 2008:9:17-23.
PubMed
5) Tamagunone L, Artigiani S, Chen H et al. Plexins are a large family of receptors for transmembrane, secreted and PI-anchored semaphorins in vertebrates. Cell 1999; 99:71-80.
 
6) Nogi T, Yasui N, Mihara E et al. Structural basis for semaphoring signaling through the plexin receptor. Nature 2010; 467:1123-1127.
 
7) Kumanogoh A, Marukawa S, Suzuki K et al. Class 4 semaphorin Sema 4A enhances T-cell activation and interacts with Tim-2. Nature 2002; 419; 629-633.
 
8) Kumanogoh A, Watanabe C, Lee I et al. Identification of CD 72 as a lymphocyte receptor for the class 4 semaphorin CD 100:a novel mechanism for regulating B cell signaling. Immunity 2000; 13:621-631.
 
9) Suzuki K, Okuno T, Yamamoto M et al. Semaphorin 7A initiates T-cell-mediated inflammatory responses through alpha 1 beta 1 integrin. Nature 2007; 446:680-684.
 
10) Pasterkamp RJ, Kolodkin AL. Semaphorin junction:making tracks toward neural connectivity. Curr Opin Neurobiol 2003; 12:79-89.
 
11) Kruger RP, Aurandt J, Guan K. Semaphorins command cells to move. Nat Rev Mol Cell Biol 2008; 6:789.
 
12) Takamatsu H, Takegahara N, Nakagawa Y et al. Semaphorins guide the entry of dendric cells into the lymphatics by activating myosin 2. Nat Immunol 2010; 7:594-600.
 
13) Vadasz Z, Ben-Izhak O, Bejar J et al. The involvement of immune semaphorins and neuropilin-1 in lupus nephritis. Lupus 2011; 20:1466-1473.
PubMed
14) Miller LE, Weidler C, Falk W et al. Increased prevalence of semaphorin 3C, a repellent of sympathetic nerve fibers, in the synovial tissue of patients with rheumatoid arthritis. Artiritis Rheum 2009; 50:1156-1163.
 
15) Mangasser-Stephan K, Dooley S, Welter C et al. Identification of human semaphoring E gene expression in rheumatoid synovial cells by mRNA differential display. Biochem. Biophys Res Commun 1997:234:153-156.
 
16) talano A. The neuroimmune semaphorin-3A reduces inflammation and progression of experimental autoimmune arthritis. J immunol 2010; 185:6373-6383.
 
17) Choi YI, Duke-Cohan JS, Ahmed WB et al. Plexin D 1 glycoprotein controls migration of positively selected thymocytes into the medulla. Immunity 2008; 29:888-898.
 
18) Nakagawa Y, Takamatsu H, Okuno T et al. Identification of semaphorin 4B as a negative regulator of basophil-mediated immune responses. J Immunol 2011; 186:2881-2888
 
19) Bougeret C, Mansur IG, Dastot H et al. Increased surface expression of a newly identified 150-kDa dimer early after human T lymphocyte activation. J immunol 1992:148:318-323.
 
20) Wang X, Kumanogoh A, Watanabe C et al. Functional soluble CD 100/Sema 4D released from activated lymphocytes:possible role in normal and pathologic immune responses. Blood 2001; 97:3498-3504.
 
21) Watanabe C, Kumanogoh A, Shi W et al. Enhanced immune responses in transgenic mice expressing a truncated form of the lymphocyte semaphorin CD 100. J Immunol 2001:167:4321-4328.
 
22) Besliu A, Banica L, Predeteanu D et al. Peripheral blood lymphocytes analysis detects CD 100/ SEMA 4D alteration in systemic sclerosis patients. Autoimmunity 2011; 44:427-36.
 
23) Negishi-Koga T, Shinohara M, Komatsu N et al. Suppression of bone formation by osteoclastic expression of semaphoring 4D. Nature Med 2011; 17:1473-1480.
 
24) Behar O, Golden JA, Mashimo H et al. Semaphorin 3 is needed for normal patterning and growth of nerves, bones and heart. Nature 1996; 383:525-528.
PubMed
25) Takegahara N, Takamatsu H, Toyofuku T et al. Plexin-A 1 and its interaction with DAP 12 in immune responses and bone homeostasis. Nat Cell Biol 2006; 8:615-622.
 
26) Watarai H, Sekine E, Inoue S et al. PDC-TREM, a plasmacytoid dendritic cell-specific receptor, is responsible for augmented production of type I interferon. Proc Natl Acad Sci USA. 2008:105:2993-8
 
27) Kang HR, Lee CG, Homer RJ. Semaphorin 7A plays a critical role in TGF-beta 1-induced pulmonary fibrosis. JEM 2007; 204:1083-93
 
28) Kang S, Okuno T, Takegahara N et al. Intestinal epithelial cell-derived semaphorin 7A negatively regulates development of colitis via α v β1 integrin. J Immunol 2012; 188:1108-11d 16.
 
P.139 掲載の参考文献
1) Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot Essent Fatty Acids 2005; 73:141-162.
PubMed
2) Serhan CN, Krishnamoorthy S, Recchiuti A, et al. Novel anti-inflammatory-pro-resolving mediators and their receptors. Curr Top Med Chem 2011; 11:629-647.
PubMed
3) Chiang N, Serhan CN, Dahlen SE, et al. The lipoxin receptor ALX:potent ligand-specific and stereo-selective actions in vivo. Pharmacol Rev 2006; 58:463-487.
 
4) Renda G, Zurro M, Romano M, De Caterina R. Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors. Br J Clin Pharmacol 2010; 69, 303-306.
PubMed
5) Hashimoto A, Hayashi I, Murakami Y, et al. Antiinflammatory mediator lipoxin A 4 and its receptor in synovitis of patients with rheumatoid arthritis. J Rheumatol 2007; 34:2144-2153.
PubMed
6) Chan MM, Moore AR. Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E 2-mediated lipoxin A 4 production. J Immunol 2010:1:184:6418-6426.
 
7) Kronke G, Katzenbeisser J, Uderhardt S, et al. 12/15-lipoxygenase counteracts inflammation and tissue damage in arthritis. J Immunol 2009:183:3383-3389.
PubMed
8) Kowal-Bielecka O, Kowal K, Distler O, et al. Cyclooxygenase-and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease:an imbalance between proinflammatory and antiinflammatory lipid mediators. Arthritis Rheum 2005; 52:3783-3791.
PubMed
9) Kowal-Bielecka O, Kowal K, Distler O, et al. Mechanisms of Disease:leukotrienes and lipoxins in scleroderma lung disease--insights and potential therapeutic implications. Nat Clin Pract Rheumatol 2007; 3:43-51.
PubMed
10) Martins V, Valen? a SS, Farias-Filho FA, et al ATLa an aspirin-triggered lipoxin A 4 synthetic analog, prevents the inflammatory and fibrotic effects of bleomycin-induced pulmonary fibrosis. J Immunol 2009; 182:5374-5381.
 
11) Kebir D, Jozsef L, Pan W, et al. 15-epi-lipoxin A 4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury. Am J Respir Crit Care Med 2009 15; 180:311-319.
PubMed
12) Wu SH, Liao PY, Yin PL, et al. Elevated expressions of 15-lipoxygenase and lipoxin A 4 in children with acute poststreptococcal glomerulonephritis. Am J Pathol 2009; 174:115-122.
PubMed
13) Das UN. Lipoxins as biomarkers of lupus and other inflammatory conditions. Lipids Health Dis 2011, 15; 10:76.
 
14) Yamaguchi H, Higashi N, Mita H, et al. Urinary concentrations of 15-epimer of lipoxin A(4)are lower in patients with aspirin-intolerant compared with aspirin-tolerant asthma. Clin Exp Allergy 2011; 41:1711-1718.
PubMed
15) Hao H, Liu M, Wu P, et al. Lipoxin A 4 and its analog suppress hepatocellular carcinoma via remodeling tumor microenvironment. Cancer Lett 2011; 309:85-94.
PubMed
16) Macdonald LJ, Boddy SC, Denison FC, et al. A role for lipoxin A 4 as an anti-inflammatory mediator in the human endometrium. Reproduction 2011; 142:345-352.
PubMed
17) Pajdo R, Brzozowski T, Szlachcic A, et al. Lipoxins, the novel mediators of gastroprotection and gastric adaptation to ulcerogenic action of aspirin. Curr Pharm Des 2011; 17:1541-1551.
PubMed
18) Van Dyke TE. Proresolving lipid mediators:potential for prevention and treatment of periodontitis. J Clin Periodontol 2011:38 Suppl 11:119-125.
 
19) Ho KJ, Spite M, Owens CD, et al. Aspirin-triggered lipoxin and resolvin E 1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am J Pathol 2010; 177:2116-2123.
 
20) Serhan CN, Savill J. Resolution of inflammation:the beginning programs the end. Nat Immunol 2005; 6:1191-1197.
 
P.146 掲載の参考文献
1) Bearcroft CP, Perret D, Farthing MJ. Postprandial plasma 5-hydroxytryptamine in diarrhea predominat irritable bowel syndrome:a pilot study. Gut 1998; 42:42-46.
 
2) Chey WD, Chey WY, Heath AT, et al. Long-term safety and efficacy of alocetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2004; 99:2195-2203.
PubMed
3) Caras S, Borel R, Krause G, et al. Cilansetron shows efficacy in male and female non-constipated IBS subjects in a US study. Gastroenterology 2001; 120(suppl 1):A 217.
 
4) Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006; 130; 1480-1491.
PubMed
5) 福土 審, 金澤 素, 篠崎雅江ほか:過敏性腸症候群. 心身症診断・治療ガイドライン2006. 小牧 元, 久保千春, 福土 審, 編. 東京:協和企画; 2006:11-40,
 
P.153 掲載の参考文献
1) Frisbie DD, Trotter GW, Powers BE, et al. Arthroscopic subchondral bone plate microfracture technique augments healing of large chondral defects in the radial carpal bone and medial femoral condyle of horses. Vet Surg 1999; 28:242-255.
PubMed
2) Bae DK, Yoon KH, Song SJ. Cartilage healing after microfracture in osteoarthritic knees. Arthroscopy 2006; 22:367-367.
PubMed
3) Bedi A, Feeley BT, Williams RJ 3rd. Management of articular cartilage defects of the knee. J Bone Joint Surg Am 2010; 92:994-1009.
PubMed
4) Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126:663-676.
PubMed
5) Zhou Q, Brown J, Kanarek A, et al. In vjvo reprogramming of adult pancreatic exocrine cells to betacells. Nature 2008; 455:627-632
 
6) Ieda M, Fu JD, Delgado-Olguin P, et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010; 142:375-386.
PubMed
7) Szabo E, Rampalli S, Risueno RM, et al. Direct conversion of human fibroblasts to multilineage blood progenitors. Nature 2010; 468:521-526.
PubMed
8) Vierbuchen T, Ostermeier A, Pang ZP, et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010:463:1035-1041.
PubMed
9) Pang ZP, Yang N, Vierbuchen T, et al. Induction of human neuronal cells by defined transcription factors. Nature 2011; 476:220-223.
PubMed
10) Sekiya S, Suzuki A. Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. Nature 2011; 475:390-393.
PubMed
11) Son EY, Ichida JK, Wainger BJ, et al. Conversion of mouse and human fibroblasts into functional spinal motor neurons. Cell stem cell 2011; 9:205-218.
PubMed
12) Hiramatsu K, Sasagawa S, Outani H, et al. Generation of hyaline cartilaginous tissue from mouse adult dermal fibroblast culture by defined factors, J Clin Invest 2011; 121:640-657.
PubMed
13) Akiyama H, Chaboissier MC, Martin JF, et al. The transcription factor Sox 9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox 5 and Sox 6. Genes Dev 2002; 16:2813-2828.
 
14) Smits P, Li P, Mandel J, et al. The transcription factors L-Sox 5 and Sox 6 are essential for cartilage formation. Dev Cell 2001; 1:277-290.
 
15) Ikegami D, Akiyama H, Suzuki A, et al. Sox 9 sustains chondrocyte survival and hypertrophy in part through Pik 3ca-Akt pathways. Development 2011; 138:1507-1519.
 
16) Ikeda T, Kamekura S, Mabuchi A, et al. The combination of SOX 5, SOX 6, and SOX 9 (the SOX trio) provides signals sufficient for induction of permanent cartilage. Arthritis Rheum 2004; 50:3561-3573.
 
17) Sudo K, Kanno M, Miharada K, et al. Mesenchymal progenitors able to differentiate into osteogenic, chondrogenic, and/or adipogenic cells in vitro are present in most primary fibroblast-like cell populations. Stem Cells 2007; 25:1610-1617.
PubMed
18) Outani H, Okada M, Hiramatsu K, et al. Induction of chondrogenic cells from dermal fibroblast culture by defined factors does not involve a pluripotent state. Biochem. Biophys Res Commun 2011; 411:607-612.
 
19) Nakagawa M, Takizawa N, Narita M, et al. Promotion of direct reprogramming by transformation-deficient Myc. Proc Natl Acad Sci USA 2010; 107:14152-14157.
PubMed
20) Seki T, Yuasa S, Oda M, et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell stem cell 2010:7:11-14.
PubMed
21) Maekawa M, Yamaguchi K, Nakamura T, et al. Direct reprogramming of somatic cells is promoted by maternal transcription factor Glis 1. Nature 2011; 474:225-229.
PubMed

治療と副作用

P.161 掲載の参考文献
1) P_rez C, Salda_a MT, Navarro A et al. One-Day Of Chronic Pain in Primary Care Setting in SPAIN. Pain Practice abstract March 15, 2009.
 
2) Bouhassira D, Lant_ri-Minet M, Attal N et al. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008; 136:380-387.
 
3) O'Connor AB. Neuropathic pain:quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics 2009; 27:95-112.
PubMed
4) Bennett MI, Attal N, Backonja M et al. Using screening tools to identify neuropathic pain. Pain 127; 2007:199-203.
PubMed
5) 神経障害性疼痛薬物療法ガイドライン編集:日本ペインクリニック学会神経障害性疼痛薬物療法ガイドライン作成ワーキンググループ真興交易医書出版部2011年7月.
 
6)Nakamura M, Nishiwaki Y, Ushida T et al. Prevalence and characteristics of chronic musculoskeletal pain in Japan. J Orthop Sci 2011; 16:424-432.
PubMed
7) Buntin-Mushock C, Phillip L, Moriyama K et al. Age-dependent opioid escalation in chronic pain patients. Anesth Analg 2005; 100:1740-1745.
PubMed
8) Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Griffin MR, Yared A, Ray WA. Am J Epidemiol. 2000 Mar 1; 151(5):488-96.
PubMed
9) Lee EY, Lee EB, Park BJ, et al. Tramadol 37. 5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain:a 1-week, randomized, double-blind, placebocontrolled trial. Clin Ther 2006; 28:2052-2060.
 
10) Mystakidou K, Parpa E, Tsilika E et al. Long-term management of noncancer pain with transdermal therapeutic system-fentanyl. J Pain 2003; 4:298-306.
PubMed
11) Choquette D, McCarthy TG, Rodrigues JF et al. Transdermal fentanyl improves pain control and functionality in patients with osteoarthritis:an open-label Canadian trial. Clin Rheumatol 2008:27:587-595.
PubMed
12) 塩川優一, 延永正, 斎藤輝信ら. 非ステロイド性抗炎症剤による上部消化管傷害に関する疫学調査. リウマチ1991; 31:96-111.
 
13) 矢島弘嗣, 山尾純一, 宮内義純ら. NSAIDs長期服用患者における胃粘膜障害の発症状況に関する疫学調査. Therapeutic Reseach 2006; 37:1211-1217.
 
14) 三木健司. 運動器慢性疼痛に対するデュロテップMTパッチの使用経験新薬と臨床J New Rem&Clin 2011; 60:110 (1212)-116 (1218).
 
15) 三木健司. 運動器慢性疼痛に対する新しい鎮痛薬トラムセット配合錠-51例の使用経験から考える安全な投与方法-. 新薬と臨床2011; 60巻:2358-2364.
 
P.167 掲載の参考文献
1) Bannatyne GA Lindsay J. A note on the treatment of rheumatoid arthritis by vaccines. Br Med J 1911; 1:192-193.
 
2) Ball CP. The treatment of rheumatic diseases by vaccines. Br Med J 1911; 1:1105-1106.
PubMed
3) Lider O, Karin N, Shinitsky M, et al. Therapeutic vaccination against adujvant arthritis using autoimmnen T-cells treated with hydrostatic pressur. Proc Natl Acad Sci USA 1987; 84:4577-4580.
 
4) Mor F, Lohse AW, Karin N, et al, Clinical modeling of T-cell vacccination against autoimmune disease in rats:selection of antigen-specific T-cells using a mitogen. J Clin Invest 1990; 85:1594-1598.
 
5) Custafsson K, Karlsson M, Anderson L, et al. Structures on the i-A molecule predisposing for susceptibility to type II collagen-induced autoimmune arthritis. Eur J Immunol 1990; 20:2127-2131.
 
6) Yoshino S, Yoshino J. Suppression of chronic antigen-induced arthritis in rats by a monoclonal antibody against the T-cell receptor αβ. Cell Immunol 1992:144:382-391.
 
7) Chen G, Li N, Zang YCQ. Vaccination with selected synovial T cells in rheumatoid arthritis. Arthritis Rheum 2007; 56:453-463.
 
8) Anderton SM, van der Zee R,'rakken B, et al. Activation of T cells recognizing self 60-KD heat shock protein can protect against experimental arthritis. J Exp Med 1995; 181:943-952.
 
9) van Laar JM, Miltenburg AMM, Verdonk MJA, et al. Effects of inoculation with attenuated autologous T cells in patients with rheumatoid arthritis. J Autoimmun 1993:6:159-167.
 
10) Ivanova IP, Seledtsov VI, Samarin DM, et al. Characterization of immunogenic properties of polyclonal T cell vaccine intended for the treatment of rheumatoid arthritis. Bull Exp Biol Med 2007:144:630-634.
PubMed
11) Xiao J, Li S, Wang W, et al. Protective effects of overexpression TCR V β5. 2-HSP 70 and TCR V B 8.2-HSP 70 against collagen-lnduced arthritis in rats. Cell Mol lmmunol 2007; 4:439-445.
 
12) Ping-ling GE, Li-ping MA, Wei W, et al. Inhibition of collagen-induced arthritis by DNA vaccines encoding TCR V β5.2 and TCR V β8.2. Chin Med J 2009; 122:1039-1048.
 
13) Moreland LW, Heck Jr LW, koopman WJ, et al. V β17 T-cell receptor peptide vaccine:results of a phase I dose-finding study in patients with rheumatoid arthritis. Ann NY Acad Sci 1995; 756:211-214.
 
14) Moreland LW, Heck Jr LW, Koopman WJ, et al. V β17 T-cell receptor peptide vaccination in rheumatoid arthritis:results of a phase I dose escalation. J Rheumatol 1996; 23:1353-1362.
 
15) Moreland LW, Morgan EE, Adamson TC 3rd et al. T cell receptor peptide vaccination in rheumatoid arthritis:a placebo-controlled trial using a combination of Vbeta 3, Vbeta 14, and Vbeta 17 peptides. Arthritis Rheum 1998; 41:1919-1929.
 
16) Xinqiang S, Fei L, Nan L, et al. Construction and characterization of a novel DNA vaccine that is potent antigen-specific tolerizing therapy for experimental arthritis by increasing CD 4+CD 25+Treg cells and inducing Th 1 to Th 2 shift in both cells and cytokines. Vaccine 2009; 27:690-700.
 
17) Zimmerman DH, Taylor P, Bendele A, et al. CEL-2000:A therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagentype II induced arthritis in the DBA mouse model. Intern lmmunopharmacol 2010:10:412-421.
 
18) Spohn G, Keller I, Beck M, et al. Active immunizaton with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur J Immunol 2008; 38:877-887.
 
19) Zheng X, Suzuki M, Ichim TE, et al. Treatment of autoimmune arthritis using RNA interference-modulated dendritic cells. J Immunol 2010; 184:6457-6464.
PubMed
20) Ratsimandresy RA, Duvallet E, Assier E, et al. Active immunization against IL-23p 19 improves experimental arthritis. Vaccine 2011; 29:9329-9336.
 
21) Xue H, Linag F, Liu N, et al. Potent antirheumatic activity of a new DNA vaccine targeted to B 7-2/CD 28 costimulatory signaling pathway in autoimmune arthritis. Hum Gene Ther 2011; 22:65-76.
 
P.178 掲載の参考文献
1) 柱本 照, 山根隆志, 田中千尋ら. 関節リウマチ患者の睡眠障害. 脳21 2008; 11:465-470
 
2) 菱沼典子, 小松浩子. 看護実践の根拠を問う 改定2版, 東京:南江堂; 1998.
 
3) 鈴木彩加, 大久保暢子. 看護分野におけるアロマテラピー研究の現状と課題. 聖路加看護大学紀要2009; 35:17-27.
 
4) Buysse DJ, Reynold III CF, Monk TH, et al. The Pittsburgh sleep Quality Index:A Newlnstrnment for psychiatric practice and research 1988; 28:193-213.
 
5) 土井由利子, 輪真 澄, 内山 真ら. ピッツバーグ睡眠質問票日本語版の作成. 精神科治療学1998; 13:755-763.
 
6) Ancoli-lsrael S, Cole R, Alessi C, et al. The role of actigraphy in the study of sleep and circadian rhythms. Sleep 2003; 26:342-392.
 
7) 日経メディカルオンライン 学術ダイジェクト 第10回欧州リウマチ学会 年次集会(EULAR2009).
 
8) 花岡一雄. 痛み-基礎・診断・治療-初版第1刷. 東京:朝倉書店; 2003.
 
9) 豊田久美子, 荒川千登世, 稲本 俊ら. 足浴が精神神経免疫系に及ぼす影響. 綜合看護1997; 別冊12:3-14.
 
P.183 掲載の参考文献
1) Myeloma Trialists' Collaborative Group. Combination Chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma:an overview of 6, 633 patients from 27 randomised trials. J Clin Oncol 1998; 16:3832-3842.
 
2) Barlogie B et al. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Eng J Med 1984; 310:1353-1356.
 
3) Hideshima T, et al NF-κ B as a Therapeutic Target in Multiple Myeloma THE JOURNAL OF BIOLOGICAL CHEMISTRY 2002; 277:16639-16647.
 
4) 飯田真介:再発・難治性骨髄腫に対する治療戦略と新規薬剤のさらなる開発. 臨床血液2010:51:1511-1522.
 
5) San Miguel JF, Schlag R, Khuageva NK et al. Bortezomib plus melphalan and predonisone for initial treatment of multiple myeloma N Engl J Med 2008; 359:906-917.
 
6) Mateos MV, Oriol A, Martinez-Lopez J et al. Bortezomib, melphalan and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma:a randomized trial. Lancet Oncol 2010; 11:934-941.
PubMed
7) Rajkumar SV, Jacobus S, Callander NS et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma:an open-label randomized controlled trial. Lancet Oncol 2010; 11:29-37.
PubMed
8) Richardson PG, Weller E, Lonial S et al. Lenalidomide, bortezomib, adndexamethsone combination therapy in patients with newly diagnosed multiple myeloma, Blood 2010:116:679-686.
PubMed
P.190 掲載の参考文献
1) 平成22年国民生活基礎調査の概況より抜粋, 厚生労働省ホームページ(http://www.mhlw.go.jp/toukei/saikin/hw/k-tyosa/k-tyosa10/)より
 
2) Oliveria SA, Felson DT, Reed JI, et al. Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization. Arthritis Rheum 1995; 38:1134-1141.
 
3) Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis:an update with relevance for clinical practice. Lancet 2011; 377:2115-2126.
PubMed
4) Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target:recommendations of an international task force. Ann Rheum Dis 2010; 69:631-637.
PubMed
5) Chevalier X, Goupille P, Beaulieu AD, et al. Intraarticular injection of anakinra in osteoarthritis of the knee:a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2009; 61:344-352.
PubMed
6) 川合眞一. 変形性関節症に対するAcetaminophen療法-文献調査と実態調査に基づく検討-. 薬理と治療2007; 35:785-795.
 
7) 川合眞一. 非ステロイド抗炎症薬. 日本医事新報2008; 436:43-44.
 
8) 鏑木 誠.川合眞一. 変形性関節症の治療:NSAIDsの使い方. Geriatric Medicine(老年医学). 2010; 48:343-347.
Medical*Online
9) 菅原幸子. 変形性関節症におけるセレコキシブ(YM177)のロキソプロフェンナトリウムおよびプラセボを対照とする第III相二重盲検並行群間比較試験PROGRESS IN MEDICINE 2006; 26(suppl-3):2911-2931.
 
10) 川合眞一. 関節リウマチと変形性関節症における選択的COX-2阻害薬治療学2007; 41:1205-1208.
 
11) 鏑木 誠, 川合眞一. セレコキシブ. 診断と治療2010:98:323-326.
 
12) Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs:a population-based case-control study. Arch Intern Med 2005; 165:978-984.
PubMed
13) 坂本長逸. 選択的COX-2阻害薬と心血管系リスク. 治療学2007; 41:1223-1226.
 
14) Bjordal JM, Ljunggren AE, Klovning A, et al. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain:meta-analysis of randomised placebo controlled trials. BMJ 2004; 329:1317.
PubMed
15) Zahn PK, Subieta A, Park SS, et al. Effect of blockade of nerve growth factor and tumor necrosis factor on pain behaviors after plantar incision. J Pain 2004; 5:157-163.
PubMed
16) Lane N Webster, L Lu SP, et al. RN 624 (anti-NGF)improves pain and function in subjects with moderate knee osteoarthritis:a phase I study. Arthritis Rheum 2005:52(Suppl.):S 461.
 
17) Lane N, Schnitzer T, Birbara C, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 2010; 363:1521-1531.
PubMed
18) Schnitzer T, Lane N, Birbara C, et al. Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthritis Cartilage 2011; 19:639-646.
 
19) Brown M, Murphy F, Radin D, et al. Tanezumab Reduces Osteoarthritic Knee Pain:Results of a Randomized Double-Blind. Placebo-Controlled Phase III Trial. J Pain 2012:13:790-798.
PubMed
20) Wood J. Nerve growth factor and pain. N Engl J Med 2010; 363:1572-1573.
 
21) Echtermeyer F, Bertrand J, Dreier R, et al. Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis. Nat Med 2009; 15:1072-1076.
PubMed
22) Shimizu S, Asou Y, Itoh S, et al. Prevention of cartilage destruction with intraarticular osteoclastogenesis inhibitory factor/osteoprotegerin in a murine model of osteoarthritis. Arthritis Rheum 2007; 56:3358-3365.
 
23) Miyaki S, Sato T, Inoue A, et al. MicroRNA-140 plays dual roles in both cartilage development and homeostasis. Genes Dev 2010:24:1173-1185.
PubMed
P.200 掲載の参考文献
1) O'Shea JJ, Pesu M, Borie DC, et al. A new modality for immunosuppression:targeting the JAK/STAT pathway. Nat Rev Drug Discov 2004; 3:555-564.
PubMed
2) Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003; 302:875-878.
PubMed
3) Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis:results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690, 550 versus placebo. Arthriis Rheum 2009; 60:1895-1905.
PubMed
4) Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib(CP-690, 550)or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012; 64:617-629.
PubMed
5) Ivashkiv LB. Cross-regulation of signaling by ITAM-associated receptors. Nature Immunology 2009; 10:340-347.
PubMed
6) Taniguchi T, Kobayashi T, Kondo J, et al. Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis. J Biol Chem 266(24):15790-6, 1991
PubMed
7) Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor:A twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008; 58:3309-3318.
PubMed
8) Genovese MC, Kavanaugh A, Weinblatt ME, et al. An oral Syk kinase inhibitor in the treatment of rheurnatoid arthritis:a three-month randomized placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 2011; 63:337-345.
PubMed
9) Kontzias A, Laurence A, Gadina M, et al. Kinase inhibitors in the treatment of immune-mediated disease. F1000 Med Rep 2012; 4:5. Epub 2012 Mar 1.
 
10) Alberts B, et al. Molecular Biology of The Cell 5th Edition Newton Press, 2010.
 
P.207 掲載の参考文献
1) Holick M. Vitamin D deficiency. N Engl J Med 2007; 357:266-281.
PubMed
2) Holick MF, Vitamin D:evolutionary, physiological and health perspectives. Curr Drug Targets 2011; 12:4-18.
PubMed
3) 上西一弘. 栄養面からみたビタミンDの重要性と新たな評価. 薬局2008:59:11-14.
 
4) 岡野登志夫. ビタミンD代謝の基礎と臨床臨床検査2011; 55:957-965.
 
5) 須田立雄ビタミンDがホルモンとして位置づけられる理由. 薬局2008:59:3-9.
 
6) 松尾壽之, 本澤真弓. ホルモンの作用. 上代淑ヒト監訳ハーパー・生化学原書25版. 東京:丸善; 2001:572-588.
 
7) Baeke F, Takiishi T, Korf H et al. Vitamin D:modulator of the immune system. Curr Opin Pharmacol 2010:10:482-496.
PubMed
8) http://www.ncbi.nlm.nih.gov/gene/1594
 
9) 伊藤裕, 柴田洋孝. 内分泌疾患総論改定第7版. 小川聡 総編集. 内科学書第5巻. 東京:中山書店; 2009:2-24.
 
10) Cutolo M, Pizzorni C, Sulli A:Vitamin D endocrine system involvement in autoimmune rheumatic diseases. Autoimmun Rev 2011:11:84-87.
PubMed
11) Van Belle TL Gysemans C, Mathieu C. Vitamin D in autoimmune, infectious and allergic diseases:A vital player? Best Pract Res Clin Endocrinol Metab 2011; 25:617-632.
 
12) 中山耕之介. ビタミンDと免疫システム. ホルモンと臨床2006:54:769-777.
 
13) Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity:new aetiological and therapeutic considerations. Ann Rheum Dis 2007; 66:1137-1142.
PubMed
14) Hewison M. Vitamin D and the Immune System:New Perspectives on an Old Theme. Endocrinol Metab Clin North Am 2010; 39:365-379.
 
15) Guillot X, Semerano L, Saidenberg-Kermanac'hN, et al:Vitamin D and inflammation. Joint Bone Spine 2010; 77:552-557.
 
16) Takeuchi A, Reddy GS, Kobayashi T, et al. Nuclear factor of activated T cells (NFAT)as a molecular target for 1alpha, 25-dihydroxyvitamin D 3-mediated effects. J Immunol 1998; 160:209-218.
 
17) Cippitelli M, Santoni A. Vitamin D 3:a transcriptional modulator of the interferon-gamma gene. Eur J Immunol 1998; 28:3017-3030.
PubMed
18) Hewison M Vitamin D and innate and adaptive immunity. Vitam Horm 2011; 86:23-62.
PubMed
19) Di Rosa M, Malaguarnera M, Nicoletti F, et al. Vitamin D 3:a helpful immuno-modulator. Immunology 2011; 134:123? 139.
 
20) Verstuyf A, Carmeliet G, Bouillon R, et al. Vitamin D:a pleiotropic hormone. Kidney Int 2010; 78:140-145.
PubMed
21) Mohr SB, Garland CF, Gorham ED, et al. The association between ultraviolet B irradiance, vitamin D status and incidence rates of type 1 diabetes in 51 regions worldwide. Diabetologia 2008; 51:1391-1398.
PubMed
22) Hypp nen E, L r E, Reunanen A, et al. Intake of vitamin D and risk of type 1 diabetes:a birth-cohort study. Lancet 2001; 358:1500-1503.
 
23) Bizzarri C, Pitocco D, Napoli N, et al. No Protective Effect of Calcitriol on β-Cell Function in Recent-Onset Type 1 Diabetes:The IMDIAB XIII trial. Diabetes Care 2010; 33:1962-1963.
 
24) Beretich BD, Beretich TM. Explaining multiple sclerosis prevalence by ultraviolet exposure:a geospatial analysis. Mult Scler 2009:15:891-898.
PubMed
25) v Meuth SG, Bittner S, Ulzheimer JC, et al. Therapeutic approaches to multiple sclerosis:an update on failed, interrupted, or inconclusive trials of neuroprotective and alternative treatment strategies. Bio Drugs 2010:24:317-330.
 
26) Neovius M, Simard JF, Askling J, et al. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Ann Rheum Dis 2011; 70:624-629.
PubMed
27) Cutolo M, Otsa K, Laas K, et al. Circannual vitamin d serum levels and disease activity in rheumatoid arthritis:Northern versus Southern Europe. Clin Exp Rheumatol 2006; 24:702-704.
PubMed
28) Iikuni N, Nakajima A, Inoue E, et al. What's in season for rheumatoid arthritis patients? Seasonal fluctuations in disease activity. Rheumatology(Oxford)2007; 46:846-848.
PubMed
29) Mouterde G, Lukas C, Logeart I, et al. Predictors of radiographic progression in the ESPOIR cohort:the season of first symptoms may influence the short-term outcome in early arthritis. Ann Rheum Dis 2011; 70:1251-1256.
PubMed
30) Patel S, Farragher T, Berry J, et al. Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheum 2007; 56:2143-2149.
PubMed
31) Merlino LA, Curtis J, Mikuls TR, et al. Vitamin D intake is inversely associated with rheumatoid arthritis:Results from the Iowa Women's Health Study. Arthritis Rheum 2004:50:72-77.
PubMed
32) Nielen MMJ, van Schaardenburg D, Lems WF, et al. Vitamin D deficiency does not increase the risk of rheumatoid arthritis:Comment on the article by Merlino et al. Arthritis Rheum 2006; 54:3719-3720.
 
33) Tikly M, Navarra SV:Lupus in the developing world--is it any different? Best Pract Res Clin Rheumatol 2008; 22:643-655.
PubMed
34) Bae SC, Fraser P, Liang MH. The epidemiology of systemic lupus erythematosus in populations of African ancestry:a critical review of the "prevalence gradient hypothesis". Arthritis Rheum 1998; 41:2091-2099.
PubMed
35) Gilkeson G, James J, Kamen D, et al. The United States to Africa lupus prevalence gradient revisited Lupus 2011; 20:1095-1103.
PubMed
36) Zold E, Barta Z, Bodolay E. Vitamin D deficiency and connective tissue disease. Vitam Horm 2011; 86:261-286.
PubMed
37) Kamen DL, Cooper GS, Bouali H, et al. Vitamin D deficiency in systemic lupus erythematosus. Auto-immun Rev 2006; 5:114-117.
 
38) Gatenby PA, Lucas RM, Engelsen O, et al. Antineutrophil cytoplasmic antibody-associated vasculitides:could geographic patterns be explained by ambient ultraviolet radiation? Arthritis Rheum 2009; 61:1417-1424.
PubMed
39) Zold E, Szodoray P, Nakken B, et al. Alfacalcidol treatment restores derailed immune-regulation in patients with undifferentiated connective tissue disease. Autoimmun Rev 2011; 10:155-162.
PubMed
P.214 掲載の参考文献
1) O'Shea JJ, Murray PJ. Cytokine signaling modulates in inflammatory responses. Immunity 2008:28:477-487.
 
2) Yamaoka K Saharinen P, Pesu M, et al. The Janus kinases (Jaks). Genome Biol 2004; 5:253.
PubMed
3) Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003; 302:875-878.
PubMed
4) Chrencik JE, Patny A, Leung IK, et al. Structural and thermodynamic characterization of the TYK 2 and JAK 3 kinase domainsin complex with CP-690550 and CMP-6. J Mol Biol 2010; 400:413-433.
 
5) Milici AJ, Kudlacz EM, Audolyl, et al. Cartilage preservation by inhibition of Janus Kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther 2008; 10:R 14.
 
6) Meyer DM, Jesson M, Li X, et al. Anti-lnflammatory Activity and Neutrophil Reductions Mediated by the Jak 1/Jak 3 Inhibitor, CP-690, 550, in Rat Adjuvant-lnduced Arthritis. Journal of Inflammation 2010; 7:41.
 
7) Flanagan ME, Blumenkopf TA, Brissette WH, et al. Discovery of CP-690, 550:a potent and selective Janus kinase(JAK)inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem 2010; 53:8468-8484.
PubMed
8) Park HB, Oh K, Garmaa N, et al. CP-690550, a Janus Kinase Inhibitor, Suppresses CD 4+T-Cell-Mediated Acute Graft-Versus-Host Disease by lnhibiting the Interferon-Gamma Pathway. Transplantation 2010; 90:825-835.
 
9) Paniagua R, Si MS, Flores MG, et al. Effects of Jak 3 Inhibition with CP-690, 550 on Immune Cell Populations and Their Functions in Nonhuman Primate Recipients of Kidney Allografts. Transplantation(in press)
 
10) Maeshima K, Yamaoka K, Kubo S, et al. A JAK inhibitor tofacitinib regulates synovitis through inhibition of IFN-γand IL 17 production by human CD 4+T cells. Arthritis Rheum (in press)
 
11) Tanaka Y, Suzuki M, Nakamura H, et al. hase II study of tofacitinib (CP-690, 550)combined with methorrexate in patints with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res 2011:63:1150-1158.
 
12) Tanaka Y, Takeuchi T, Yamanaka H, et al. Tofacitinib(CP-690, 550), an oral Janus kinase inhibitor, as monotherapy in Japanese patients with active rheumatoid arthritis:a 12-week phase 2b study abstract]. Arthritis Rheum 2011:64:#2192.
 
13) van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690, 550), an oral Janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis:a 24-month phase 3 study[abstract]. Arthritis Rheum 2011:64:#2592.
 
14) Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis:results of a double-blind, placebo-controlled phase IIa trial of three dose levels of CP-690, 550 versus placebo. Arthritis Rheum 2009; 60:1895-1905.
 
15) Coombs JH, Bloom BJ, Breedveld FC, et al. Improved Pain, Physical Functioning and Health Status in Patients with Rheumatoid Arthritis Treated with CP-690, 550, an Orally Active Janus Kinase (Jak)Inhibitor:Results from a Randomised Double-Blind, Placebo-Controlled Trial. Ann Rheurn Dis 2010:69:413-416.
PubMed
16) van Vollenhoven RF, Fleischmann RM, Cohen SB, et al. Tofacitinib(CP-690, 550), An Oral Janus Kinase Inhibitor, or Adalimumab Versus Placebo in Patients with Rheumatoid Arthritis on Background Methotrexate:A Phase 3 Study[abstract]. Arthritis Rheum 2011; 63 Suppl:#408.
 
17) Burmester G, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690, 550), an oral Janus Kinase inhibitor, in combination with methotrexate, in patients with active rheumatoid arthritis with an inadequate response to tumor necrosis factor-inhibitors:a 6-month phase 3 study. abstract]. Arthritis Rheum 2011; 64:#718.
 
18) Tanaka Y, Maeshima Y, Yamaoka K. In vitro and in vivo analysis of a Jak inhibitor in rheumatoid arthritis. Ann Rheum Dis(in press).
 
19) Fleischmann RM, Kremer JM, Cush JJ, et al. Phase 3 Study of Oral JAK Inhibitor Tasocitinib (CP-690, 550)Monotherapy in Patients with Active Rheumatoid Arthritis[abstract]. Arthritis Rheum 2010; 62 (Suppl):#L 8.
 
20) Greenwald M, Fidelus-Gort RK, Levy R, et al. A randomized, dose-ranging, placebo-controlled study of INCB 028050, a selective JAK 1 and JAK 2 inhibitor, in subjects with active rheumatoid arthritis abstract]. Arthritis Rheum 2010; 62:#2172.
 
P.222 掲載の参考文献
1) Infante-Duarte C, Horton HF, Byrne MC, et al. Microbial lipopeptides induce the production of IL-17in Th cells. J Immunol 2000; 165:6107-6115.
 
2) 梅村正幸, 松崎吾朗. IL-17におけるマイコバクテリア感染制御防御. 実験医学2007; 25:3164-3169.
 
3) Witowski J, Ksiazek K, Jorres A. Interleukin-17:a mediator of inflammatory response. Cell Mol Life Sci 2004; 61:567-579.
 
4) 佐伯行彦. IL-17(Interleukin-17). 七川歡次監修. リウマチ病セミナーXIX. 大阪:永井書店; 2008:121-128.
 
5) 井川 宣. 脊椎関節炎とRAでのTNF阻害剤の治療効果の違いとHLA-B27の関与. 日本脊椎関節炎学会誌 2010; 2:39-45.
Medical*Online
6) Wellcome Trust Case Consortium & Australo-American Spondylitis Consortium. Association scan of 14,500 nonsynonymous SNPs in four diseasea identifies autoimmunity variants. Nature Gen 2008; 39:1329-1337.
 
7) 藤本 学. Th17系を標的とする抗体療法Update-抗IL-12/23p40抗体と抗IL-17抗体. 実験医学2010; 28:2036-2040.
 
8) Genovese MC, Durez P, Richards HB, et al. One Year Efficacy and Safety Results of a Phase II Trial of Secukinumab in Patients with Rheumatoid Arthritis. Arthritis Rheum 2011; 63:S 149.
 
9) Baraliakos X, Braun J, Laurent DD, et al. Interleukin-17A Blockade with Secukinumab Reduces Spinal Inflammation in Patients with Ankylosing Spondylitis As Early As Week 6, As Detected by Magnetic Resonance Imaging. Arthritis Rheum 2011; 63:S972.
 
10) Schett G, Landewe R, van der Heijde D. Tumornecrosis factor blockers and structural remodelling in ankylosing spondylitis:what is reality and what is fiction? Ann Rheum Dis 2007; 66:709-711.
 
11) 高柳 広. Osteoimmunology の進歩. Frontiers in Rheumatology & Clinical Immunology 2007; 1:39-46.
Medical*Online
12) Mclnnes I, Sieper J, Braun J, et al. Anti-Interleukin 17A Monoclonal Antibody Secukinumab Reduces Signs and Symptoms of Psoriatic Arthritis in a 24-Week Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. Arthritis Rheum 2011; 63:S306.
 
13) Genovese MC, Durez P, Richards HB, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody in patients with rheumatoid arthritis. Ann Rheum Dis (in submit)
 

手術

P.228 掲載の参考文献
1) Valentin B. Geshichite der Orthopadie. Stuttgart:Georg Thime Verlag 1961:187-190.
 
2) 加藤 正. 外反母趾の病態と手術的治療の検討. 整・災外1982; 25:111-117.
 
3) 星野 達, 外反母趾変形の検討. 別冊整形外科1994; 25:276-279.
 
4) 日本整形外科学会ガイドライン委員会. 外反母趾ガイドライン. 南江堂; 2008:10-11.
 
5) Tanaka Y. Radiographic analysis of hallux valgus. A two-dimensional coordinate system J Bone Joint Surg 1995; 77-A:205-213.
PubMed
6) Hardy RH. Observation on hallux valgus. Based on a controlled series. J Bone Joint Surg 1951; 33-B:376-391.
 
7) Akin O. The treatment of hallux valgus-a new operation procedure and its results. Med Sentinel 1925; 33:678-679.
 
8) Mitchell CL, Fleming JL, Allen R, et al. Osteotomy-bunionectomy for hallux valgus. J Bone Joint Surg 1958:40-A:41-58.
PubMed
9) Mann RA, Rudicel S, Graves SC. Repair of hallux valgus with a distal soft-tissue procedure and proximal metatarsal osteotomy. J Bone Joint Surg 1992; 74-A:124-129.
PubMed
10) Magnan B, et al. Percutaneous distal metatarsal osteotomy for correction of hallux valgus. J Bone Joint Surg 2005; 87-A:1191-1199.
PubMed
11) 田中康仁. イラストでみる必修手術テクニック外反母趾(2)第1中足骨水平骨切り術. 関節外科2004; 23:731-736.
 
12) Barouk LS. Die metatarsalosteotomienach Weil zurbehandlung der metatarsalgie. Orthopade 1996; 25:338-344.
PubMed
13) Okuda R, Kinoshita M, Morikawa J, et al. Surgical treatment for hallux valgus with painful plantar callosities. Foot Ankle Int 2001:22:203-208.
PubMed
P.240 掲載の参考文献
1) Verbiest H. A radicular syndrome from developmental narrowing of the lumbar vertebral canal. J Bone Joint Surg Br 1954; 36:230-237.
PubMed
2) Whitesides TE Jr. To the Editor:Re. The effect of an interspinous implant on intervertebral disc pressures by Swanson et al. Spine 2003; 28:26-31. Spine 2003; 28:1906-1908.
 
3) Christie SD, Song JK, Fessler RG. Dynamic interspinous process technology. Spine 2005; 30:573-578.
 
4) Kabir SMR, Gupta SR, Casey ATH. Lumbar interspinous spacers. A systematic review of clinical and biomechanical evidence. Spine 2010; 35:E 1499-E 1506.
 
5) Bono CM, Vaccaro AR. Interspinous process devices in the lumbar spine. J Spinal Disord Tech 2007; 20:255-261.
PubMed
6) Lo TP Jr, Salerno SS, Colohan ART. Interlaminar spacer:A review of its mechanism, application, and efficacy. World Neurosurgery 2010; 74:617-626.
PubMed
7) Szpalski M, Gunzburg R, Colloca C et al. Chirurgie du rachis du sujet age:radiculalgie, canal retreci:particularites, enjeux, resultats? Revue du rhumatisme monographies 2011; 78:46-53.
 
8) Nishida K, Doita M, Kakutani K et al. Development of percutaneously insertable/removable interspinous processs spacer for treatment of posture-dependent lumbar spinal-canal stenosis:preclinical feasibility study using porcine model. Eur Spine J DOI 10. 1007/s 00586-011-2129-3.
 
9) Lazaro BCR, Brasiliense LBC, Sawa AGU et al. Biomechanics of a novel minimally invasive lumbar interspinous spacer:Effects on kinematics, facet loads, and foramen height. Neurosurgery 2010; 66[ONS Suppl 1]; ons 126-ons 133.
 
10) Menchetti PP, Postacchini F, Bini W et al. Percutaneous surgical treatment in lumbar spinal stenosis with Aperius-Perc LID:Indications, surgical technique and results. Acta Neurochir Suppl 2011; 108:183-186.
 
11) Gunzburg R, Szpalski M, Callary SA et al. Effect of a novel interspinous implant on lumbar spinal range of motion. Eur Spine J 2009; 18:696-703.
PubMed
12) Yano S, Hida K, Seki T et al. A new ceramic interspinous process spacer for lumbar spinal canal stenosis. Neurosurgery 2008; 63 ONS Suppl 1]:ons 108-ons 116.
 
13) 西田康太郎, 前野耕一郎, 角谷賢一朗ら. 腰部脊柱管狭窄症に対する最小侵襲手術を目的とした腰椎棘突起間スペーサーの開発:ヒト屍体と大型動物を用いた前臨床試験.J Spine Res 2011; 2:487.
 
14) Wilke HJ, Drumm J, Haussler K et al. Biomechanical effect of different lumbar interspinous implants on flexibility and intradiscal pressure. Eur Spine J 2008; 17:1049-1056.
PubMed
15) Lindsey DP, Swanson KE, Fuchs P et al. The effects of an interspinous implant on the kinematics of the instrumented and adjacent levels in the lurnbar spine. Spine 2003; 28:2192-2197.
PubMed
16) Siddiqui M, Karadimas E, Nicol M et al. Influence of X Stop on neural foramina and spinal canal area in spinal stenosis. Spine 2006; 31:2958-2962.
PubMed
17) Wiseman CM, Lindsey DP, Fredrick AD et al. The effect of arl interspinous process implant on facet loading during extension. Spine 2005; 30:903-907.
 
18) Zucherman JF, Hsu KY, Hartjen CA et al. A prospective randomized multi-center study for the treatment of lumbar spinal stenosis with the X STOP interspinous implant:1-year results. Eur Spine J 2004; 13:22-31.
PubMed
19) Richards JC, Majumdar S, Lindsey DP et al. The treatment mechanism of an interspinous process implant for lumbar neurogenic intermittent claudication. Spine 2005; 30:744-749.
PubMed
20) Lee J, Hida K, Seki T et al. An interspinous process distractor(X STOP)for lumbar spinal stenosis in elderly patients. Preliminary experiences in 10 consecutive cases, J Spinal Disord Tech 2004; 17:72-77.
 
21) Swanson KE, Lindsey DP, Hsu KY et al. The effects of an interspinous implant on intervertebral disc pressures. Spine 2003; 28:26-32.
PubMed
22) 立入久和, 長谷 斉, 橋本秀輝ら. 局所麻酔で行う棘突起間スペーサー(Sten-XTM)による腰部脊柱管狭窄症の治療経験. 脊椎・脊髄神経手術手技2004; 6:120-123.
 
23) Phillips FM, Voronov LI, Gaitanis IN et al. Biomechanics of posterior dynamic stabilizing device (DIAM)after facetectomy and discectomy. The Spine Journal 2006; 6:714-722.
PubMed
24) Traitwein FT, Dipl-lng FH, Lowery GL et al. Determination of the in vivo posterior loading environment of the Coflex interlaminar-interspinous implant. The Spine Journal 2010; 10:244-251.
 
25) Lafage V, Gangnet N, Senegas J et al. New interspinous implant evaluation using an in vitro biomechanical study combined with an finite-element analysis. Spine 2007; 32:1706-1713.
 
26) Zucherman JF, Hsu KY, Hartjen CA et al. A multicenter, prospective, randomized trial evaluating the X STOP interspinous process decornpression system for the treatment of neurogenic intermittent claudication. Two-year follow-up results. Spine 2005; 30:1351-1358.
PubMed
27) Kondrashov DG, Hannibal M, Hsu KY et al. Interspinous process decompression with the X-STOP device for lumbar spinal stenosis. A 4-year follow-up study. J Spinal Disord Tech 2006:19:323-327.
 
28) Anderson PA, Tribus CB, Kitchel SH. Treatment of neurogenic claudication by interspinous decompression:application of the X STOP device in patients with lumbar degenerative spondylolisthesis. J Neurosurg Spine 2006; 4:464-471.
 
29) Kondrashov DG, Hannibal M, Hsu KY et al. X-STOP versus decompression for neurogenic claudication:economic and clinical analysis. The Internet J Minim Invasive Spinal Technology 2007; 1 (number 2).
 
30) Siddiqui M, Smith FW, Wardlaw D. One-year results of X STOP interspinous implant for the treatment of lumbar spinal stenosis. Spine 2007; 32:1345-1348.
PubMed
31) Verhoof OJ, Bron JL, Wapstra FH et al. High failure rate of the interspinous distraction device (X-Stop)for the treatment of lumbar spinal stenosis caused by degenerative spondylolisthesis. Eur Spine J 2008; 17:188-192.
PubMed
32) Brussee P, Hauth J, Donk RD et al. Self-rated evaluation of outcome of the implantation of interspinous process distraction (X-Stop)for neurogenic claudication. Eur Spine J 2008; 17:200-203.
PubMed
33) Kuchta J, Sobottke R, Eysel P et al. Two-year results of interspinous spacer (X-Stop)implantation in 175 patients with neurogenic intermittent claudication due to lumbar spinal stenosis. Eur Spine J 2009; 18:823-829.
PubMed
34) Bowers C, Amini A, Dailey AT et al. Dynamic interspinous process stabilization:review of complications associated with X-Stop device. Neurosurg Focus 2010; 28:1-6.
PubMed
35) Tuschel A, Chavanne A, Eder C et al. Implant survival analysis and failure modes of the X STOP interspinous distraction device. Spine 2011 Feb 9[Epub ahead of print]. PMID:21311406
 
36) Caserta S, La Maida GA, Misaggi B et al. Elastic stabilization alone or combined with rigid fusion in spinal surgery:a biomechanical study and clinical experience based on 82 cases. Eur Spine J 2002; 11 (Suppl 2):S 192-S 197.
PubMed
37) Talor J, Pupin P, Delaioux S et al. Device for intervertbral assisted motion:technique and initial results. Neurosurg Focus 2007; 22:E 6.
 
38) Hrabalek L, Machac J, Vaverka M. The DIAM spinal stabilization system to treat degenerative disease of the lumbosacral spine. Acta Chir Orthop Traumatol Cech 2009; 76:417-423.
PubMed
39) Fabrizi AP, Maina R, Schiabello L. Interspinous spacers in the treatment of degenerative lumbar spinal disease:our experience with DIAM and Aperius devices. Eur Spine J 2011; 20 (Suppl 1):S 20-S 26.
 
40) Buric J, Pulidori M. Long-term reduction in pain and disability after surgery with the interspinous device for intervertebral assisted motion (DIAM)spinal stabilization system in patients with low back pain:4-year follow-up from a longitudinal prospective case series. Eur Spine J DOI 10.1007/s OO586-011-1697-6 (Published online:29 January 2011
 
41) Richter A, Schutz C, Hauck M et al. Does an interspinous device (Coflex TM)improve the outcome of decompressive surgery in lumbar spinal stenosis? One-year follow-up of a prospective case control study of 60 patients. Eur Spine J 2010:19:283-289.
 
42) Senegas J. Mechanical supplementation by non-rigid fixation in degenerative intervertebral lumbar segments:the Wallis system. Eur Spine J 2002; 11(Suppl 2):S 164-S 169
 
43) Floman Y, Millgram MA, Smorgick Y et al. Failure Of the Wallis interspinous implant to lower the incidence of recurrent lumbar disc herniations in patients undergoing primary disc excision. J Spinal Disord Tech 2007; 20:337-341.
PubMed
44) Senegas J, Vital JM, Pointillart V et al. Clinical evaluation of a lumbar interspinous dynamic stabilization device (the Wallis system)with a 13-year mean follow-up. Neurosurg Rev 2009; 32:335-342.
PubMed
45) Korovessis P, Repantis T, Zacharatos S et al. Does Wallis implant reduce adjacent segment degeneration above lurnbosacral instumented fusion? Eur Spine J 2009; 18:830-840.
 
46) Sobottke R, Rollinghoff M, Siewe J et al. Clinical outcomes and quality of life 1 year after open microsurgical decompression or imlantation of an interspinous stand-alone spacer. Minim Invasive Neurosurg 2010; 53:179-183.
PubMed
47) Postacchini R, Ferrari E, Cinotti G et al. Aperius interspinous implant versus open surgical decompression in lumbar spinal stenosis. The Spine Journal 2011; 11:933-939.
PubMed
48) Barbagallo GMV, Olindo G, Corbino L et al. Analysis of complications in patients treated with the X-Stop interspinous process decompression system:proposal for a novel anatomic scoring system for patient selection and review of the literature. Neurosurgery 2009:65:111-120.
PubMed
49) Sobottke R, Schluter-Brust K, Kaulhausen T et al. Interspinous implants (X Stop(R), Wallis(R), Diam(R))for the treatment of LSS:is there a correlation between radiological parameters and clinical outcome? Eur Spine J 2009; 18:1494-1503
 
50) Miller JD, Miller MC, Lucas MG. Erosion of the spinous process:a potential cause of interspinous process spacer failure. Report of 2 cases. J Neurosurg Spine 2010; 12:210-213.
 
51) Kim DH, Tantorski M, Shaw J et al. Occult spinous process fractures associated with interspinous prccess spacers. Spine 2011; 36:E 1080-E 1085.
 
52) Tamburrelli FC, Proietti L, Logroscino CA. Critical analysis of lumbar interspinous devices failures:a retrospective study. Eur Spine J 2011; 20 (Suppl 1):S 27-S 35.
 
53) Epstein NE. How often is minimally invasive minimally effective:what are the complication rates for minimally invasive surgery? Surgical Neurology 2008; 70:386-389.
PubMed
54) Benzel EC, Mroz T. Interlaminar spacers:looks good smells bad World Neurosurgery 2010; 74:576-578.
PubMed
55) Hsieh PC. The efficacy of surgical treatment for lumbar stenosis with the X-STOP:An issue in need of a closer inspection. World Neurosurgery 2012 May 24[Epub ahead of print]PMID:22634461
 
P.251 掲載の参考文献
1) Matsusue Y, Hama H, Yamamuro T. Arthroscopic multiple osteochondral transplantation to the chondral defect in the knee associated with anterior cruciate ligament disruption. Arthroscopy 1993; 9:318-321.
 
2) Brittberg M, Lindahl A, Nilsson A, et al. Treatrnent of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med 1994; 331:889-895.
 
3) Hunzicker EB, Rosenberg LC. Repair of partial-thickness defects in articular cartilage:cell recruitment from the synovial membrane. J Bone Joint Surg Am 1996 78:721-733.
 
4) Vasara AI, Hyttinen MM, Pulliainen O, et al. Immature porcine knee cartilage lesions show good healing with or without autologous chondrocyte transplantation. Osteoarthritis Cartilage 2006; 1066-1074.
PubMed
5) Steadman JR, Rodkey WG, Rodrigo JJ. Microfracture:Surgical technique and rehabilitation to treat chondral defects. Clin Orthop 2001:391:362-369.
 
6) Steadman JR, Briggs KK WG, Rodrigo JJ, et al. Microfracture for traumatic chondral defects of the knee:average 11-year follow-up. Arthroscopy 2003; 19:477-484.
 
7) Minas T, Gomoll AH, Rosenberger R, et al. Increased failure rate of autogenous chondrocyte implantation after previous treatment with marrow stimulation techniques. Am J Sports Med 2009; 37:902-908.
 
8) Yamashita F, et al. The transplantation of an autogeneic osteochondral fragment for osteochondritis dissecans of the knee. Clin Orthop 1985; 201:43-50.
PubMed
9) Matsusue Y, Nakamura T, Suzuki S, et al. Biodegradable pin fixation of osteochondral fragments of the knee. Clin Orthop 1996; 322:166-173.
PubMed
10) Hangody L, Kish G, Karpati Z, et al. Osteochondral plugs:Autogenous osteochondral mosaicplasty for the treatment of focal chondral and osteochondral articular defects. Op Tech in Orthopaedics 1997:7 (4):312-322.
 
11) Matsusue Y, Nakagawa Y, Kotake T, et al. Arthroscopic osteochondral autograft transplantation for chondral lesion of the tibial plateau of the knee. Arthroscopy 2001:17:653-659.
PubMed
12) Matsusue Y, Nakagawa Y, Nakamura T. Articular cartilage repair of the knee with autogenous osteochondral plug transplantation (mosaicplasty). In The 1st Congress of Asia Pacific Knee Society (Tokyo)February 18-20, 2000.
 
13) Nakagawa Y, Matsusue Y, Nakamura T. Osteochodral graft transplantation for steroid-induced osteonecrosis of the femoral condyle. Lancet 2003; 362:402.
 
14) Matsusue Y, Kikkawa M, Nakagawa Y, et al. Mosaicplasty for chondral/osteochondral lesions of the knee. In The International Symposium on Cartilage Repair (Hiroshima)February, 2004.
 
15) Matsusue Y, Kubo M, Nakagawa Y. Autogenous bone-cartilage transplantation. Tech in Knee Surg 2010; 9:85-94.
 
16) Hangody L, Dobos J, Balo E, et al. Clinical experience with autogenous osteochondral mosaicplasty in an athletic population:A 17-year prospective multicenter study. Am J Sports Med 2010; 38:1125-1133.
 
17) Gortz S, Allison J, Young BS, et al. Fresh osteochondral allografting for steroid-associated osteonecrosis for the femoral condyle. Clin Orthop 2010; 468:1269-1278.
 
18) Chu CR, Convery FR, Akeson WH at al. Articular cartilage transplantation. Clinical results in the knee. Clin Orthop 1999; 360:159-168.
 
19)Ghazavi MT, Pritzker KP, Davis AM, et al. Fresh osteochondral allografts for post-traumatic osteochondral defects of the knee. J Bone Joint Surg Br. 1997; 79:1008-1013.
PubMed
20) Gross AE, Kim W, Las Heras F, et al. Fresh osteochondral allografts for posttraumatic knee defects:long-term follow up. Clin Orthop 2008; 466:1863-1870.
 
21) Stone K, Walgenbach AW, Freyer A, et al. Articular cartilage paste grafting to full-thickness articular cartilage knee joint lesions:A 2-to 12-year follow-up. Arthroscopy 2006; 22:291-299.
PubMed
22) Lu Y, Dhanaraj S, Wang Z, et al. Minced cartilage without cell culture serves as an effective intraoperative cell source for ccartilage repair. J Orthop Res 2006; 24:1261-1270.
PubMed
23) Cole BJ, Farr J, Winalski CS, et al. Outcomes after a single-stage procedure for cell-based cartilage repair. Am J Sports Med 2011; 39:1170-1179.
PubMed
24) Gobbi A, Karnatzikos G, Scotti C, et al. One-step cartilage repair with bone marrow aspirate concentrated cells and collagen matrix in full-thickness knee cartilage lesions:Results at 2-year follow-up. Cartilage 2011; 2:286-299.
PubMed
25) Siclari A, Mascaro G, Gentili C, et al. A cell free scaffold-based cartilage repair provides improved function hyaline-like repair at one year. Clin Orthop 2012; 470:910-919.
PubMed
26) Niederaurer GG, Lee DR, Sankaran S. Bone grafting in arthroscopy and sports medicine. Sports Med Arthrosc Rev 2006; 14:163-168.
 
27) Kon E, Delcogliano M, Filardo G, et al. Novel nano-composite multilayered biomaterial for osteochondral regeneration. A pilot clinical trial. Am J Sports Med 2011:39:1180-1190.
PubMed
28) Peterson L, Minas T, Brittberg M, et al. Two-to 9-year outcome after autologous chondrocyte transplantation of the knee. Clin Orthop 2000; 374:212-234.
PubMed
29) Peterson L, Vasiliadis HS, Brittberg M, et al. Autologous chondrocyte implantation:a long-term follow-up. Am J Sports Med 2010:1117-1124.
PubMed
30) Wood JJ, Malek MA, Frassica FJ, et al. Autologous cultured chondrocytes:Adverse events reported to the United States Food and Drug Administration. J Bone Joint Surg Am 2006; 88:503-507.
 
31) Bartlett W, Skinner JA, Gooding CR, et al. Autologous chondrocyte implantation versus matrix-induced autologous chondrocyte implantation for osteochondral defects of the knee. A prospective randomized study. J Bone Joint Surg Br 2005; 87:640-645.
PubMed
32) Saris DB, Vanlauwe J, Victor J, et al. Treatment of symptomatic cartilage defects of the knee. Characterized chondrocyte implatation results in better clinical outcomes at 36 months in randomized trial compared to microfracture. Am J Sports Med 2009; 37:10S-19S.
 
33) Ochi M, Uchio Y, Kawasaki K, et al. Transplantation of cartilage-like tissue made by tissue engineering in the treatment of cartilage defects of the knee. J Bone Joint Surg Br 2002; 84:571-578.
PubMed
34) Zheng M-H, Willers C, Kirilak L, et al. Matrix-induced autologous chondrocyte implantation(MACI):biological and histological assessment. Tissue Eng 2007; 13:737-746.
PubMed
35) Ebert JR, Lloyd DG, Wood DJ, et al. Clinical and magnetic resonance imaging-based outcomes to 5 years after matrix-induced autologous chondrocyte implantation to address articular cartilage defects in thekmee. Am J Sports Med 2011; 39:753-763.
 
36) Marcacci M, Berruto M, Brocchetta D at al. Articular cartilage engineering with Hyalograft C. 3-year clinical results. Clin Orthop 2005; 435:96-105.
 
37) Filardo G, Kon E, Martino AD, et al. Arthroscopic second-generation autogenous chondrocyte implantation. Am J Sports Med 2011; 39:2153-2160.
 
38) Bedi A, Feeley BT, Williams RJ. Current concepts review. Management of articular cartilage defects of the knee. J Bone Joint Surg 2010; 92A:994-1009.
 
39) Crawford DC, Heveran CM, Cannon WD, et al. An autognous cartilage tissue implant Neo Cart for treatment of grade III chondral injury to the distal femur. Prospective clinical safety trial at 2 years. Am J Sports Med 2009; 37:1334-1343.
 
40) Kreuz PC, MUIIer S, Freymann U, et al. Repair of focal cartilage defects with scaffold-assisted autologous chondrocyte grafts. Clinical and biomechanical results 48 months after transplantation. Am J Sports Med 2011; 39:1697-1705.
 
41) Selmi TAS, Verdonk P, Chambat P, et al. Autologous chondrocyte implantation in a novel alginateagarose hydrogel. J Boe Joint Surg 2008; 90B:597-604.
 
42) Schneider U, Rackwitz L, Andereya S, et al. A prospective multicenter study on the outcome of type I collagen hydrogel-based autogenous chondrocyte implantation(CARES)for the repair of articular cartilage defects in the knee. Am J Sports Med 2011; 39:2258-2265.
 
43) Niemeyer P, Pestka JM, Kreuz PC, et al. Characteristic complications after autologous chondrocyte implantation for cartilage defects of the knee joint. Am J Sports Med 2008; 36:2091-2099.
PubMed
44) Sharpe JR, Ahmed SU, Fleetcroft JP, et al. The treatment of osteochondral lesions using a combination of autologous chondrocyte implantation and autograft. Three-year follow-up. J Bone Joint Surg Br 2005; 87:730-735.
PubMed
45) Wakitani S, Mitsuoka T, Nakamura N, et al. Autologous bone marrow stromal cell transplantation for repair of full-thickness articular cartilage defects in human patellae; two case reports. Cell Transplant 2004; 13:331-334.
 
46) Wakitani S, Okabe T, Horibe S, et al. Safety of autologous bone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months. J Tissue Eng Regen Med. 2011; 5:146-150.
PubMed
47) Haleeman AM, Singergy AAE, Sabry D, et al. The clinical use of human culture-expanded autogenous bone marrow mesenchymal stem cells transplanted on platelet-rich fibrin glue in the treatment of articular cartilage defects:A pilot study and preliminary results. Cartilage 2010:1:253-261.
 
48) Sakaguchi Y, Sekiya I, Yagishita K, et al. Comparison of human stem cells derived from various mesenchymal tissues:superiority of synovium as a cell source. Arthrithis Rheum 2005; 52:2521-2529.
 
49) Ando W, Tateishi K, Hart Da et al. Cartilage repair using an in vitro generated scaffold-free tissue-engineered construct using porcine mesenchymal stem cells Biomaterials 2007; 28:5462-5470.
 
50) Dragoo JL, Samimi B, Zhu M, et al. Tissue engineered cartilage and bone using stem cells from human infrapatellar fat pads. J Bone Joint Surg Br. 2003; 85:740-747.
PubMed
51) Knutsen G, Drogset JO, Engebretsen L, et al. A randomized trial comparing autogenous chondrocyte implantation with microfracture. Findings at five years. J Bone Joint Surg Am 2007; 89:2105-2112.
 
52) Horas U, Pelinkovic D, Herr G, et al. Autologous chondrocyte implantation and osteochondral cylinder transplantation in cartilage repair of the knee. A prospective, comparative trial. J Bone Joint Surg Am 200385:185-192.
 
53) Bently G, Biant LC, Carrington RW, et al. A prospective, randomized comparison of autologous chondrocyte implantation versus mosaicplasty for osteochondral defects of the knee. J Bone Joint Surg Br 2003; 85:223-230.
 
54) Gudas R, Kalesinskas RJ, Kimtys V, et al. A prospective randomized clinical study of mosaic osteo-chondral autologous transplantation versus microfracture for the treatment of osteochondral defects in the knee joint in young athletes. Arthroscopy 2005:21:1066-1075.
 
55) Nakamura N, Miyama T, Engebretsen L, et al. Cell-based therapy in articular cartilage lesions of the knee. Arthroscopy 2009; 25:531-552.
PubMed
56) Jakobsen RB, Engebretsen L, Slauterbeck JR. An analysis of the quality of cartilage repair studies. J Bone Joint Surg 2005; 87B:2232-2239.
 
57) Benthien J, Schwaninger M, Behrens P. We do not have evidence based methods for the treatment of cartilage defects in the knee. Knee Surg Sports Traumatol Arthrosc 2011; 19:543-552.
PubMed

書評

最近チェックした商品履歴

Loading...